Page last updated: 2024-11-04

cefixime

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cefixime is a third-generation cephalosporin antibiotic. It is used to treat a variety of bacterial infections, including those of the respiratory tract, urinary tract, and skin. Cefixime is effective against a broad spectrum of gram-negative bacteria, including Escherichia coli, Haemophilus influenzae, and Klebsiella pneumoniae. It is also effective against some gram-positive bacteria, such as Streptococcus pneumoniae. Cefixime is typically taken orally, and it is available in both tablet and suspension forms. Cefixime is synthesized by a multi-step process that involves the reaction of a cephalosporin nucleus with a suitable side chain. The synthesis of cefixime is a complex process that requires a number of specialized reagents and conditions. Cefixime is studied because it is an effective antibiotic with a relatively low rate of side effects. It is also important to study cefixime because it is often used to treat infections that are resistant to other antibiotics. The mechanism of action of cefixime involves the inhibition of bacterial cell wall synthesis. Cefixime is an important antibiotic because it is effective against a wide range of bacteria. It is also important because it is generally well-tolerated. Cefixime is typically used to treat bacterial infections, including those of the respiratory tract, urinary tract, and skin.'

Cefixime: A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cefixime : A third-generation cephalosporin antibiotic bearing vinyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is used in the treatment of gonorrhoea, tonsilitis, pharyngitis, bronchitis, and urinary tract infections. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2675
MeSH IDM0328108
PubMed CID5362065
CHEMBL ID1541
CHEBI ID472657
SCHEMBL ID24945
MeSH IDM0328108
PubMed CID6321411
CHEMBL ID427069
CHEBI ID93248
SCHEMBL ID49534
SCHEMBL ID24946
MeSH IDM0328108

Synonyms (148)

Synonym
79350-37-1
cefixime
FT-0664428
FT-0664429
FT-0603047
HMS3373G05
mfcd00865020
(6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
7-{2-(2-amino-1,3-thiazol-4-yl)[(carboxymethoxy)imino]acetamido}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DTXSID20861014
SY077396
(6r,7r)-7-[(z)-2-(2-amino-4-thiazolyl)-2-[(carboxymethoxy)imino]acetamido]-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
AC-4350
BRD-K71059170-001-02-5
fk-027
cl-284635
tricef
cephoral
necopen
cefspan
oroken
fr-17027
denvar
suprax
(6r,7r)-7-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(carboxymethyl)oxy]imino}acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
NCGC00179521-01
BPBIO1_000622
BSPBIO_000564
AB00513842
C06881
cefixime anhydrous
DB00671
(-)-cefixim
cfix
cefixime (inn)
D00258
PRESTWICK3_000462
cefixima [spanish]
fr 17027
cefixim
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)((carboxymethoxy)imino)acetyl)amino)-3-ethenyl-8-oxo-, trihydrate, (6r-(6alpha,7beta(z)))-
(6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(z)-(o-(carboxymethyl)oxime)trihydrate
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2z)-(2-amino-4-thiazolyl)((carboxymethoxy)imino)acetyl)amino)-3-ethenyl-8-oxo-, (6r,7r)-
cefiximum [latin]
(6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(z)-(o-(carboxymethyl)oxime) trihydrate
unixime
fk 027
cl 284635
cefixoral
brn 6025058
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid,7-(((2-amino-4-thiazolyl)((carboxymethoxy)imino)acetyl)amino)3-ethenyl-8-oxo-, trihydrate, (6r-(6alpha,7beta(z)))-
cl 284,635
anhydrous cefixime
CHEMBL1541
citropen
smr001307271
MLS002222332 ,
7beta-{(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido}-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid
(6r,7r)-7-({(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetyl}amino)-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cefiximum
chebi:472657 ,
cefixima
oraken
unii-97i1c92e55
HMS2096M06
C-2469
cefixime [usan:usp:inn:ban:jan]
unii-xz7bg04gjx
xz7bg04gjx ,
dtxsid7022754 ,
dtxcid702754
(6r,7r)-7-[-2-(2-amino-thiazol-4-yl)-2-carboxymethoxyimino-acetylamino]-8-oxo-3-vinyl-5-thia-1-aza-b
HMS2234J21
S4596
AKOS015961135
(6r,7r)-7-(((2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethyloxyimino)acetyl)amino)-3-ethenyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid trihydrate
C04 ,
cefixime [mi]
cefixime [who-dd]
(6r,7r)-7-((2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl)amino)-3-ethenyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
cefixime [inn]
AKOS015854940
CCG-220462
SCHEMBL24945
cefixime, antibiotic for culture media use only
CS-4820
cid_5362065
bdbm84007
HY-B1381
(6r,7r)-7-[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SR-01000760706-4
sr-01000760706
(6r,7r)-7-[[(2z)-2-(2-amino-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
HMS3713M06
BRD-K71059170-001-08-2
A13697
NCGC00179521-03
Q27290799
(6s,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7r)-7-[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
EN300-22411574
Z2568664267
7beta-((2z)-2-(2-amino-1,3-thiazol-4-yl)-2-((carboxymethoxy)imino)acetamido)-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid
(6r,7r)-7-(((2z)-2-(2-amino-1,3-thiazol-4-yl)-2-((carboxymethoxy)imino)acetyl)amino)-3-ethenyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
j01da23
cefixime (mart.)
cefiximum (latin)
cefixime (ep monograph)
cefixime (usp-rs)
cefixime (usp monograph)
PRESTWICK2_000462
NCGC00016938-01
cas-79350-37-1
HMS1569M06
NCGC00185001-01
CHEMBL427069
tox21_110694
cefixime(e)-form
97164-56-2
u7rwt9j78o ,
cefixime anhydrous, (e)-
(6r,7r)-7-(((2e)-2-(2-amino-4-thiazolyl)-2-((carboxymethoxy)imino)acetyl)amino)-3-ethenyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2e)-2-(2-amino-4-thiazolyl)-2-((carboxymethoxy)imino)acetyl)amino)-3-ethenyl-8-oxo-, (6r,7r)-
unii-u7rwt9j78o
EPITOPE ID:116227
BRD-K04993501-001-01-9
SCHEMBL49534
SCHEMBL24946
J-501698
(6r,7r)-7-[[(2z)-2-(2-amino-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene -2-carboxylic acid
OKBVVJOGVLARMR-QSWIMTSFSA-N
(6r,7r)-7-((z)-2-(2-aminothiazol-4-yl)-2-((carboxymethoxy)imino)acetamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7r)-7-[[(2e)-2-(2-aminothiazol-4-yl)-2-(carboxymethyloximino)acetyl]amino]-8-keto-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate
(6r,7r)-7-[[(2e)-2-(2-amino-4-thiazolyl)-2-(carboxymethoxyimino)-1-oxoethyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate
(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate
(6r,7r)-7-[[(2e)-2-(2-azanyl-1,3-thiazol-4-yl)-2-(2-hydroxy-2-oxoethyloxyimino)ethanoyl]amino]-3-ethenyl-8-oxidanylidene-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate
cid_56642849
bdbm88962
J-005196
CHEBI:93248
(e)-cefixime (cefixime ep impurity d)
[6r-[6alpha,7beta(e)]]-7-[[(2-amino-4-thiazolyl)[(car
(6r,7r,e)-7-(2-(2-aminothiazol-4-yl)-2-(carboxymethoxyimino)acetamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cefiximetrihydrate
Q163901
gtpl10898
(e)-cefixime
(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

Research Excerpts

Overview

Cefixime is a third generation orally administered cephalosporin that is frequently used as a broad spectrum antibiotic against various gram-negative and gram-positive bacteria. It is prescribed for the treatment of otitis media, respiratory tract infections, and uncomplicated urinary tract infections.

ExcerptReferenceRelevance
"Cefixime is an antibiotic from the cephalosporin class used to treat various bacterial infections. "( Clinical pharmacokinetics of cefixime: a systematic review.
Ajmal, M; Alqahtani, F; Aziz, M; Imran, I; Majeed, A; Rasool, MF; Rehman, AU; Saeed, H; Zamir, A, 2023
)
2.64
"Cefixime is a third generation orally administered cephalosporin that is frequently used as a broad spectrum antibiotic against various gram-negative and gram-positive bacteria. "( A sensitive fluorescent sensor based on the photoinduced electron transfer mechanism for cefixime and ctDNA.
Bai, AM; Hu, YJ; Liu, YC; Xu, C; Yang, CZ, 2020
)
2.22
"Cefixime (CEF) is a cephalosporin antibiotic that is used against bacterial infections."( Quantitative analysis of solid dosage forms of cefixime using Raman spectroscopy.
Ahmad, S; Ali, S; Bajwa, J; Bakkar, MA; Bashir, S; Farooq, S; Hussain, AI; Hyat, H; Kashif, M; Majeed, MI; Nawaz, H; Rashid, N, 2020
)
1.54
"Cefixime is a cephalosporin-type beta-lactam antibiotic commonly used for the management of several infections."( A Case of Acute Generalized Exanthematous Pustulosis by Cefixime with Oral Mucosal Involvement.
Akarapu, TL; Baloju, D; Bamini, T; Golla, VK; Ismail, M; Namoju, R, 2020
)
1.53
"Cefixime is a third-generation oral cephalosporin antibiotic widely used to treat bacterial infections. "( A Green, Economic "Switch-On" Sensor for Cefixime Analysis Based on Black Soya Bean Carbon Quantum Dots.
Li, C; Ma, H; Wang, J; Wu, W; Zhang, Y, 2020
)
2.27
"Cefixime is a widely used third-generation cephalosporin schedule H1 drug, which is prescribed for the treatment of otitis media, respiratory tract infections, and uncomplicated urinary tract infections and is effective against infections caused by "( Cefixime-associated acute generalized exanthematous pustulosis: Rare cases in India.
Kalaiselvan, V; Kumar, AP; Kumar, V; Medhi, B; Saurabh, A; Sidhu, S; Thota, P,
)
3.02
"Cefixime is an antibiotic which has a wide range of applications in medicine."( Surface plasmon resonance of gold nanoparticles as a colorimetric sensor for indirect detection of Cefixime.
Elhami, S; Masoudyfar, Z, 2019
)
1.45
"Cefixime is a third-generation cephalosporin and is widely used in clinical practice in childhood."( Cefixime-induced oculogyric crisis.
Bayram, E; Bayram, MT; Hiz, S; Turkmen, M, 2012
)
2.54
"Cefixime is an oral third generation cephalosporin, frequently used in respiratory tract infections (RTI) in the pediatric population. "( Clinical role of Cefixime in community-acquired infections.
Aliu, A; Basha, N; Daka, A; Doda-Ejupi, T; Dreshaj, Sh; Geca, Nj; Kabashi, S; Mustafa, A; Shala, N; Tolaj, IQ, 2011
)
2.15
"Cefixime is a unique third-generation oral cephalosporin. "( Clinical pharmacology of cefixime in unweaned calves.
Glickman, A; Lavy, E; Winkler, M; Ziv, G, 1995
)
2.04
"Cefixime is an orally active third generation cephalosporin with in vitro antibacterial activity against most important lower respiratory pathogens. "( Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections.
Brogden, RN; Markham, A, 1995
)
3.18
"Cefixime is an orally administered cephalosporin with physicochemical properties able to account for a possibly significant biliary excretion. "( [Kinetics of cefixime biliary clearance in cholecystectomized patients].
Brogard, JM; Jehl, F; Westphal, JF,
)
1.94
"Cefixime is an amino-thiazolyl cephalosporin with an extended spectrum of antibacterial activity inhibiting beta-lactamase-producing respiratory pathogens."( Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections.
Chick, TW; Neu, HC, 1993
)
1.26
"Cefixime proved to be an effective oral drug in this open treatment trial and was associated with minimal side effects."( Cefixime in the treatment of enteric fever in children.
Farid, Z; Girgis, NI; Kilpatrick, ME; Podgore, JK; Sultan, Y, 1993
)
2.45
"Cefixime is a viable alternative to amoxicillin for infants and children with acute otitis media when: (1) a beta-lactamase-producing H."( Review of cefixime in the treatment of otitis media in infants and children.
Bluestone, CD, 1993
)
1.41
"Cefixime is an extended-spectrum oral cephalosporin with activity against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, the most commonly isolated bacterial pathogens."( Cefixime in the treatment of patients with lower respiratory tract infections: results of US clinical trials.
Quintiliani, R,
)
2.3
"Cefixime is a safe, effective, and cheaper oral option for the treatment of multidrug-resistant enteric fever. "( Cefixime: an oral option for the treatment of multidrug-resistant enteric fever in children.
Billoo, AG; Memon, HI; Memon, IA, 1997
)
3.18
"Cefixime seems to be an acceptable alternative to the regimens containing an aminopenicillin and an aminoglycoside for the treatment of community-acquired non-complicated APN."( [Cefixime versus amoxicillin plus netilmicin in the treatment of community-acquired non-complicated acute pyelonephritis].
Almela, M; García San Miguel, J; Marco, F; Martínez, JA; Mensa, J; Moreno-Martínez, A; Soriano, E; Vila, J, 1998
)
2.65
"Cefixime is a third-generation oral cephalosporin that is highly active against a broad range of gram-negative and some gram-positive aerobic bacteria. "( Cefixime in urinary tract infections with special reference to pediatrics: overview.
Cataldi, L; Fanos, V, 2001
)
3.2
"Cefixime is a new orally effective third-generation cephalosporin. "( Evaluation of cefixime biliary disposition in the isolated perfused rabbit liver model and in humans.
Blickle, JF; Brogard, JM; Jehl, F; Monteil, H; Schloegel, M; Westphal, JF, 1992
)
2.09
"Cefixime is a new oral cephalosporin with in vitro activity similar to that of third-generation cephalosporins. "( [Biliary excretion and hepatic disposal of cefixime: experimental and clinical study].
Blickle, JF; Brogard, JM; Dorner, M; Jehl, F; Monteil, H; Westphal, JF, 1992
)
1.99
"Cefixime is a new oral cephamycin antibiotic with a broad spectrum of antibacterial activity in vitro. "( Cefixime vs amoxicillin in the treatment of acute otitis media in infants and children.
Marchisio, P; Principi, N, 1991
)
3.17
"Cefixime is a new orally active cephalosporin, with a broad spectrum of antibacterial activity, including Enterobacteriaceae, Haemophilus influenzae, Branhamella catarrhalis, Streptococcus pneumoniae and Streptococcus pyogenes."( Cefixime shows good effects on group A and group B beta-haemolytic streptococci.
Berlinghieri, MC; Carbone, M; Casini, A; De Luca, M; Fera, MT; Focà, A; Liberto, MC; Puccio, R, 1991
)
2.45
"Cefixime is a cephalosporin antibiotic that is more active against Proteus spp."( An improved selective medium for the isolation of Escherichia coli O157.
Chapman, PA; Jewes, L; Siddons, CA; Zadik, PM, 1991
)
1
"Cefixime is an orally absorbed cephalosporin that is active against resistant gonococci and has pharmacokinetic activity suitable for single-dose administration."( A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group.
Covino, JM; Douglas, JM; Ehret, JM; Handsfield, HH; Hook, EW; McCormack, WM; Reichart, CA; Verdon, MS, 1991
)
1.3
"Cefixime is a new third generation oral cephalosporin that exhibits excellent antibacterial activity against Neisseria gonorrhoeae, including beta-lactamase-positive strains. "( [Cefixime therapy in patients with proven gonorrhea].
Backhaus, A; Tinzl, J, 1990
)
2.63
"Cefixime is a new orally active third-generation cephalosporin with a broad spectrum of activity against a variety of both gram-positive and -negative bacteria including many beta-lactamase-producing strains of streptococci, Haemophilus influenzae, Neisseria gonorrhoeae, and the majority of the Enterobacteriaceae. "( Cefixime.
Caravaggio, C; Leggett, NJ; Rybak, MJ, 1990
)
3.16
"Cefixime is a new oral cephalosporin antibiotic with improved activity against Gram-negative pathogens comparable to the parenteral third generation cephalosporins, high beta-lactamase stability and a long elimination half-life of about 3 h. "( Concentration of cefixime in bile, gallbladder wall and serum after preoperative administration in patients undergoing cholecystectomy.
Fleckenstein, G; Moorthi, K; Nies, B, 1990
)
2.06
"Cefixime is an example of the latter."( [Cefixime, the first oral third-generation cephalosporin].
Roche, G, 1989
)
1.91
"Cefixime (CFM) is a new hemi-synthetic orally active cephalosporin which exhibits a particular affinity for PBPs 3, 1a, 1bs. "( [Antibacterial effect of cefixime].
Duval, J; Meyran, M; Soussy, CJ, 1989
)
2.02
"Cefixime is a new oral cephalosporin with the same activity as that of third generation cephalosporins, particularly against organisms responsible for lower respiratory tract infections. "( [Efficacy and tolerability of cefixime in lower respiratory tract infections in adults. French multicentric study].
Modai, J, 1989
)
2.01
"Cefixime is a new oral antibiotic with in vitro activity similar to that of parenteral third generation cephalosporins. "( [Efficacy and tolerability of cefixime in urinary tract infections in adults. A French multicentric study].
Modai, J, 1989
)
2.01
"Cefixime is a new orally active cephalosporin. "( [Comparative study of intravenous ceftriaxone followed by oral cefixime versus ceftriaxone alone in the treatment of severe upper urinary tract infections].
Regnier, B, 1989
)
1.96
"Cefixime is a new oral cephalosporin antibiotic, with broad-spectrum of activity, near than of third generation cephalosporin, especially against betelactamase producers bacteria. "( [Tonsil diffusion of cefixime in children].
Baron, S; Bégué, P; Garabedian, N; Quinet, B, 1989
)
2.04
"Cefixime is an orally absorbable cephalosporin with an extended spectrum of in vitro activity for gram-negative bacteria especially members of the Enterobacteriaceae. "( Activity of cefixime (FK 027) for resistant gram-negative bacilli.
Eng, RH; Smith, SM, 1988
)
2.1
"Cefixime is a new oral cephalosporin currently undergoing clinical trials. "( In vitro protein binding interaction studies involving cefixime.
Bialer, M; Faulkner, RD; Silber, BM; Wu, WH; Yacobi, A,
)
1.82
"Cefixime is a new oral cephalosporin which shows dose dependent absorption and concentration dependent serum protein binding in dogs. "( Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding.
Bialer, M; Look, ZM; Silber, BM; Wu, WH; Yacobi, A, 1987
)
2.04
"Cefixime is a new orally absorbed iminomethoxy, aminothiazolyl cephalosporin. "( In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime.
Neu, HC, 1987
)
1.94
"Cefixime is an orally absorbed third generation cephalosporin with a broad spectrum of activity against Gram-positive and Gram-negative bacteria and is highly resistant to beta-lactamase degradation. "( Pharmacokinetic profile of cefixime in man.
Barone, JS; Faulkner, RD; Kaplan, SA; Silber, BM; Yacobi, A, 1987
)
2.01

Effects

Cefixime has a long elimination half-life (3 hours compared with 0.5 hours for cefaclor and 1.5 Hours for Cefalexin), which allows once daily administration. It has little activity against Staphylococcus aureus and is inactive against Pseudomonas aeruginosa.

ExcerptReferenceRelevance
"Cefixime has a long elimination half-life (3 hours compared with 0.5 hours for cefaclor and 1.5 hours for cefalexin), which allows once daily administration."( Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections.
Brogden, RN; Markham, A, 1995
)
2.46
"Cefixime has a long elimination half-life (3 hours compared with 0.5 hours for cefaclor and 1.5 hours for cefalexin), which allows once daily administration."( Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections.
Brogden, RN; Markham, A, 1995
)
2.46
"Cefixime activity has been determined against Haemophilus influenzae strains producing or not beta-lactamase, or resistant to ampicillin by non-enzymatic mechanism. "( [In vitro effect of cefixime against Haemophilus influenzae].
Dabernat, H; Delmas, C, 1989
)
2.04
"Cefixime has little activity against Staphylococcus aureus and is inactive against Pseudomonas aeruginosa."( Cefixime. A review of its antibacterial activity. Pharmacokinetic properties and therapeutic potential.
Brogden, RN; Campoli-Richards, DM, 1989
)
2.44
"Cefixime has been assayed with microbiological method in tonsils of 21 children (mean age 59 months)."( [Tonsil diffusion of cefixime in children].
Baron, S; Bégué, P; Garabedian, N; Quinet, B, 1989
)
1.32
"Cefixime overall has excellent in vitro activity against the commonly encountered respiratory and urinary tract pathogens."( In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime.
Neu, HC, 1987
)
1.22

Actions

ExcerptReferenceRelevance
"Cefixime was able to inhibit the growth of serovar Typhimurium inhabiting monocyte-derived THP-1 cells."( Mechanism of therapeutic effectiveness of cefixime against typhoid fever.
Ikeda, F; Ikemoto, A; Matsumoto, K; Matsumoto, Y; Tawara, S; Wakai, Y, 2001
)
1.3

Treatment

The treatment with cefixime was successful in 30/30 (100%) patients suffering from acute otitis media (AOM), in 10/12 (83.3%) with acute sinusitis, in 12/12 patients ( 100%) with pneumonia, and in 31/35 (88.57) with uncomplicated UTI.

ExcerptReferenceRelevance
"Cefixime treatment failure, defined as the repeat isolation of N. "( Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada.
Allen, VG; Lee, C; Low, DE; Martin, IE; Melano, RG; Mitterni, L; Rebbapragada, A; Seah, C; Siebert, H; Towns, L, 2013
)
2.07
"The treatment with cefixime was successful in 30/30 (100%) patients suffering from acute otitis media (AOM), in 10/12 (83.3%) with acute sinusitis, in 12/12 patients (100%) with pneumonia, in 31/35 (88.57) with uncomplicated UTI. "( Clinical role of Cefixime in community-acquired infections.
Aliu, A; Basha, N; Daka, A; Doda-Ejupi, T; Dreshaj, Sh; Geca, Nj; Kabashi, S; Mustafa, A; Shala, N; Tolaj, IQ, 2011
)
1.04

Toxicity

Adverse events occurred in 29 percent of clarithromycin-treated patients and 23 percent of the cefixime- treated patients. One hundred thirty-seven (49 percent) of the 279 cefIXime-treated and 126 (44 percent) of the 286 amoxicillin-treatment patients reported at least one adverse experience during the study.

ExcerptReferenceRelevance
" Although five patients had transient episodes of mild diarrhea, no significant adverse reaction was observed."( Efficacy and safety of oral cefixime therapy in common infectious diseases in children.
Chen, JM; Huang, LM; Hwang, KC; Lee, CY; Lee, MJ; Lee, PI,
)
0.43
" Adverse effects were not reported during the study."( Safety and efficacy of cefixime versus cefaclor in respiratory tract infections.
Dorow, P, 1989
)
0.59
" One hundred thirty-seven (49 percent) of the 279 cefixime-treated and 126 (44 percent) of the 286 amoxicillin-treated patients reported at least one adverse experience during the study."( A double-blind, multicenter, comparative study of the safety and efficacy of cefixime versus amoxicillin in the treatment of acute urinary tract infections in adult patients.
Bryant, A; Iravani, A; Johnson, D; Richard, GA, 1988
)
0.76
" The incidence of adverse clinical experiences and occurrence of laboratory abnormalities were similar to those seen with other beta-lactam antimicrobial agents."( Safety profile of cefixime.
Cartwright, K; Desjardins, RE; McCarthy, EF; Tally, FP, 1987
)
0.61
" Adverse experiences were similar in adults and children in all groups, with the most frequent side effects being gastrointestinal in nature."( A review of the safety profile of cefixime.
Wu, DH,
)
0.41
" It has been administered to over 5,000 patients worldwide and has been shown to be a safe and effective treatment for acute bacterial exacerbations of chronic bronchitis and bacterial pneumonia when given twice daily (250 to 500 mg)."( Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections.
Chick, TW; Neu, HC, 1993
)
0.54
" Adverse events occurred in 29 percent of the clarithromycin-treated patients and 23 percent of the cefixime-treated patients."( Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections.
Chick, TW; Neu, HC, 1993
)
0.76
"This study demonstrated that CFX has comparable clinical efficacy and a better adverse events profile than A/C when used to treat AOM of childhood."( Comparison of the efficacy, safety and acceptability of cefixime and amoxicillin/clavulanate in acute otitis media.
Gooch, WM; Philips, A; Rhoades, R; Rosenberg, R; Schaten, R; Starobin, S, 1997
)
0.54
" Physical examination, evaluation of complaints, collection of data on adverse reactions, and bacteriological analysis of urine were performed after enrollment in the study at visit 2 (day 10 +/- 1) and 3 (day 35 +/- 2)."( [The efficacy and safety of cefixime and amoxicillin/clavulanate in the treatment of asymptomatic bacteriuria in pregnant women: a randomized, prospective, multicenter study].
Dovgan', EV; Filippenko, NG; Gustovarova, TA; Khlybova, SV; Kozyrev, IuV; Likhikh, DG; Novoselova, AV; Rafal'skiĭ, VV,
)
0.43
"To compare the incidence and types of adverse effects between 3 recommended treatment options for gonorrhea and to compare the incidence of injection site pain between single-dose intramuscular ceftriaxone and gentamicin."( Safety of Single-Dose Oral Cefixime, Intramuscular Ceftriaxone, or Intramuscular Gentamicin for the Treatment of Gonorrhea: A Systematic Review and Meta-analysis.
Dresser, J; Wilby, KJ, 2021
)
0.92
"Comparator studies reporting adverse effect outcomes of treatment with cefixime, ceftriaxone, or gentamicin for gonorrhea in humans were included."( Safety of Single-Dose Oral Cefixime, Intramuscular Ceftriaxone, or Intramuscular Gentamicin for the Treatment of Gonorrhea: A Systematic Review and Meta-analysis.
Dresser, J; Wilby, KJ, 2021
)
1.15
"The use of single-dose cefixime, ceftriaxone, and gentamicin-based regimens for treatment of gonorrhea appears to be safe and acceptable for use in practice."( Safety of Single-Dose Oral Cefixime, Intramuscular Ceftriaxone, or Intramuscular Gentamicin for the Treatment of Gonorrhea: A Systematic Review and Meta-analysis.
Dresser, J; Wilby, KJ, 2021
)
1.23
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32

Pharmacokinetics

The pharmacokinetic parameters of cefixime were determined in healthy volunteers following oral administration of 200 mg. The time for maximum serum concentration was delayed, as a reflect of increased volume of distribution resulting from ascites and hypoalbuminemia.

ExcerptReferenceRelevance
"Bacteriological, pharmacokinetic and clinical studies on cefdinir (CFDN, FK482), a new oral cephalosporin, 5% and 10% granules, were performed in the field of pediatrics."( [Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field].
Hatakeyama, K; Hori, M; Nakano, K; Sakaguchi, N; Sugita, M; Toyonaga, Y; Yamazaki, M; Yamori, K, 1992
)
0.28
"A pharmacokinetic study on cefixime (CFIX) 5% granules for pediatric use was performed, and pharmacokinetic parameter were calculated."( [Pharmacokinetic studies on oral antibiotics in pediatrics. I. A pharmacokinetic study on cefixime in pediatrics].
Iwai, N; Nakamura, H, 1991
)
0.8
"The pharmacokinetic parameters of cefixime were determined in healthy volunteers following oral administration of 200 mg cefixime as tablet, syrup and dry suspension, respectively."( [Pharmacokinetics of cefixime in volunteers and a literature comparison with the new ester prodrug cephalosporins].
Kees, F; Naber, KG, 1990
)
0.88
"The dependence of the antibacterial activity of the two oral cephalosporins cefixime and cefaclor on pharmacokinetic properties was investigated in an in vitro model using strains of enterobacteria and a streptococcal strain."( Comparative activity of cefixime and cefaclor in an in vitro model simulating human pharmacokinetics.
Nies, BA, 1989
)
0.81
" The elimination half-life varies between 3 and 4 hours."( [Pharmacokinetic properties of cefixime].
Barré, J, 1989
)
0.56
" The time for maximum serum concentration was delayed and the cefixime half-life in serum was prolonged, as a reflect of increased volume of distribution resulting from ascites and hypoalbuminemia."( [Effect of hepatic failure upon the pharmacokinetics of cefixime].
Gaudin, C; Lebrec, D; Montay, G; Roche, G; Singlas, E; Taburet, AM, 1989
)
0.76
" There was a small but significantly longer (approximately 1 h) time to peak concentration when the drug was given with food."( The pharmacokinetics of cefixime in the fasted and fed state.
Bohaychuk, W; Desjardins, RE; Faulkner, RD; Haynes, JD; Silber, BM; Yacobi, A, 1988
)
0.58
" Comparison (ANOVA) of serum and urinary excretion pharmacokinetic parameters for cefixime on days 1, 8, and 15 found no significant (P greater than ."( Pharmacokinetics of cefixime after once-a-day and twice-a-day dosing to steady state.
Bohaychuk, W; Desjardins, RE; Faulkner, RD; Haynes, JD; Look, ZM; Silber, BM; Weiss, AI, 1987
)
0.82
" The mean respective pharmacokinetic parameters obtained after the two intravenous infusions (6."( Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding.
Bialer, M; Look, ZM; Silber, BM; Wu, WH; Yacobi, A, 1987
)
0.6
" In general the half-life of the drug is about 3 to 4 hours and is not dependent on dose."( Pharmacokinetic profile of cefixime in man.
Barone, JS; Faulkner, RD; Kaplan, SA; Silber, BM; Yacobi, A, 1987
)
0.57
" Apparent total body, renal, and apparent nondialysis-nonrenal clearances and protein binding declined and elimination half-life increased with decreasing creatinine clearance."( Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency.
Brown, GR; Guay, DR; Harding, GK; Meatherall, RC, 1986
)
0.59
" After both oral and intravenous administration, the half-life of FK027 in dogs was approximately three fold that in rats."( Pharmacokinetics of FK027 in rats and dogs.
Hirose, T; Mine, Y; Sakamoto, H, 1985
)
0.27
" Plasma and urine concentrations of cefixime were determined using a reversed phase HPLC assay and pertinent pharmacokinetic parameters were estimated by model-independent standard methods."( Pharmacokinetics of cefixime in children with urinary tract infections after a single oral dose.
Kasteridou, N; Mamzoridi, K; Niopas, I; Peonides, A, 1996
)
0.89
" These pharmacokinetic data can be used as a basis to compare the four oral cephalosporins; however, comparative susceptibility data must also be considered."( Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers.
Affrime, MB; Hyatt, JM; Nix, DE; Reidenberg, P; Symonds, WT; Teal, MA; Wilton, JH,
)
0.39
" Pharmacokinetic interactions between these two classes of drugs have been described in experimental models, and exceptionally in humans."( Pharmacokinetic parameters and killing rates in serum of volunteers receiving amoxicillin, cefadroxil or cefixime alone or associated with niflumic acid or paracetamol.
Bernard, E; Carsenti-Etesse, H; De Salvador, F; Dellamonica, P; Durant, J; Farinotti, R; Roger, PM; Rouveix, B,
)
0.35
" pneumoniae/penicillin intermediate) were compared in in vitro infection models in which various human pharmacokinetic profiles of unbound antibiotic were simulated."( Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models.
Derendorf, H; Liu, P; Obermann, B; Rand, KH, 2005
)
0.55
" The method herein described was successfully applied for the evaluation of pharmacokinetic profiles of cefixime capsule in 24 healthy volunteers."( Sensitive liquid chromatography-tandem mass spectrometry method for the determination of cefixime in human plasma: application to a pharmacokinetic study.
Chen, X; Meng, F; Zeng, Y; Zhong, D, 2005
)
0.76
" The method was efficiently applied to a pharmacokinetic study in healthy volunteers."( Simultaneous determination of cefdinir and cefixime in human plasma by RP-HPLC/UV detection method: Method development, optimization, validation, and its application to a pharmacokinetic study.
Ahmad, L; Iqbal, Z; Javed, K; Khan, A; Khan, MI; Nasir, F; Shah, Y, 2011
)
0.63
" Pharmacodynamic models describing the relationship between the concentration of antimicrobials and the minimum growth rate of the bacteria provide more detailed information than the MIC only."( Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against Neisseria gonorrhoeae.
Althaus, CL; Foerster, S; Hathaway, LJ; Low, N; Unemo, M, 2016
)
0.43
" The experimental time-kill curves were analysed and quantified with a previously established pharmacodynamic model."( Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against Neisseria gonorrhoeae.
Althaus, CL; Foerster, S; Hathaway, LJ; Low, N; Unemo, M, 2016
)
0.43
" gonorrhoeae time-kill curve experiments analysed with a pharmacodynamic model have potential for in vitro evaluation of new and existing antimicrobials."( Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against Neisseria gonorrhoeae.
Althaus, CL; Foerster, S; Hathaway, LJ; Low, N; Unemo, M, 2016
)
0.43
" Drug concentration versus time data was used for pharmacokinetic calculations using one compartment model."( Disposition kinetics, renal clearance and urinary excretion of cefixime in adolescent Pakistani boys - DRUG ANALYSIS REPORT.
Asghar, D; Ashraf, MM; Bukhari, NI; Khadam, MW; Naz, U; Tahir, IM, 2019
)
0.75
"The methodology included: (i) dosing regimen selection and acquisition of pharmacokinetic data; (ii) microbiological data acquisition; and (iii) Monte Carlo simulation to estimate the PTA (probability of PK/PD target attainment) and CFR (cumulative fraction of response), as indicators of treatment success."( Are oral cefuroxime axetil, cefixime and cefditoren pivoxil adequate to treat uncomplicated acute pyelonephritis after switching from intravenous therapy? A pharmacokinetic/pharmacodynamic perspective.
Aguirre-Quiñonero, A; Canut-Blasco, A; Rodríguez-Gascón, A,
)
0.43
" The purpose of performing this review is to thoroughly evaluate the pharmacokinetic (PK) data on cefiximeFive databases were systematically searched to identify studies on the PK of cefixime."( Clinical pharmacokinetics of cefixime: a systematic review.
Ajmal, M; Alqahtani, F; Aziz, M; Imran, I; Majeed, A; Rasool, MF; Rehman, AU; Saeed, H; Zamir, A, 2023
)
1.42
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

The antibacterial, anti-biofilm and quorum sensing inhibitory activity of carvacrol alone and in combination with the antibiotic cefixime against Escherichia coli was investigated.

ExcerptReferenceRelevance
"The purpose of the present study was to elucidate the transporter-mediated pharmacokinetics mechanism of drug-drug interactions (DDIs) between bestatin and cefixime."( PEPT1- and OAT1/3-mediated drug-drug interactions between bestatin and cefixime in vivo and in vitro in rats, and in vitro in human.
Huo, X; Liu, K; Liu, Q; Ma, X; Meng, Q; Peng, J; Sun, H; Sun, P; Wang, C; Wang, L; Yang, X; Zhen, Y, 2014
)
0.83
" Ceftazidime, cefepime, and piperacillin-tazobactam in combination with amikacin showed greater activity than found in combination with ciprofloxacin."( In vitro activities of 21 antimicrobial agents alone and in combination with aminoglycosides or fluoroquinolones against extended-spectrum-β-lactamase-producing Escherichia coli isolates causing bacteremia.
Cha, MK; Cho, SY; Chung, DR; Ha, YE; Kang, CI; Kim, SH; Peck, KR; Song, JH; Wi, YM, 2015
)
0.42
"In the present study, the antibacterial, anti-biofilm and quorum sensing inhibitory activity of carvacrol alone and in combination with the antibiotic cefixime against Escherichia coli was investigated."( Antibacterial and anti-biofilm properties of carvacrol alone and in combination with cefixime against Escherichia coli.
Asadi, S; Nayeri-Fasaei, B; Shams, N; Sharifi, A; Yahya-Rayat, R; Zahraei-Salehi, T, 2023
)
1.33
" Although the participation of the particular transporters in observed drug-drug interactions can be difficult to confirm in humans, this review focuses mainly on pharmacokinetic interactions of clinically important drugs."( Transporter-mediated Drug Interactions.
Tsuji, A, 2002
)
0.31

Bioavailability

Cefixime; widely employed cephalosporin antibiotic is unfortunately coupled to poor water solubility with resultant low oral bioavailability issues. Study aimed to evaluate the potential of a novel glycoside non-ionic surfactant synthesized and characterized in our laboratory.

ExcerptReferenceRelevance
"We studied the action of nifedipine on the bioavailability of cefixime, a molecule absorbed via the gut wall dipeptide carrier system in the rat, and on the bioavailability of D-xylose, which is absorbed via a pH (and Na(+)-)-dependent transporter."( Modification of cefixime bioavailability by nifedipine in humans: involvement of the dipeptide carrier system.
Bouten, A; Carbon, C; Deslandes, A; Duverne, C; Farinotti, R; Trouvin, JH; Westphal, JF, 1992
)
0.87
"The relative bioavailability of cefixime was studied in 24 healthy male volunteers, with each subject receiving a single 400mg dose of cefixime administered as an aqueous solution, a 400mg tablet and two 200mg tablets, in a randomised crossover sequence."( Comparative bioavailability study of cefixime administered as tablets or aqueous solution.
Chassard, D; Frydman, A; Le Liboux, A; Le Roux, Y; Masala, F; Montay, G; Roche, G; Thebault, JJ; Uhlrich, J, 1991
)
0.84
" However, these cephems were not well absorbed orally."( Synthesis and biological activity of novel 3-(2-propenyl)-cephalosporins. I.
Kim, H; Kim, WJ; Ko, KY; Oh, J, 1991
)
0.28
" The best bioavailability was obtained with the dry suspension followed by the tablet and the syrup."( [Pharmacokinetics of cefixime in volunteers and a literature comparison with the new ester prodrug cephalosporins].
Kees, F; Naber, KG, 1990
)
0.6
"Three galenic formulations of cefixime (tablet, syrup and dry suspension) containing 200 mg each were compared with respect to their relative bioavailability in twelve healthy volunteers."( Relative bioavailability of three cefixime formulations.
Grobecker, H; Kees, F; Naber, KG; Sigl, G; Ungethüm, W, 1990
)
0.85
"After a 200 mg intravenous or oral dose, the absolute bioavailability of cefixime, evaluated by comparison of areas under the serum concentration-time curve values, is 50 per cent."( [Pharmacokinetic properties of cefixime].
Barré, J, 1989
)
0.79
"The advances achieved in the field of oral cephalosporins consist of improved bioavailability and enhanced intrinsic activity of the compounds."( [Structure-activity relationship of oral cephalosporins].
Bingen, E; Lambert-Zechovsky, N, 1989
)
0.28
"Interaction studies in dogs have indicated that antacids significantly decrease the oral bioavailability of cefixime."( Influence of an antacid containing aluminum and magnesium on the pharmacokinetics of cefixime.
Healy, DP; Racht, EM; Sahai, JV; Sterling, LP, 1989
)
0.71
"In a four-way cross-over study, the absolute bioavailability of cefixime was determined in 16 healthy volunteers."( Absolute bioavailability of cefixime in man.
Falkowski, AJ; Faulkner, RD; Fernandez, P; Lawrence, G; Sia, LL; Silber, BM; Weiss, AI; Yacobi, A, 1988
)
0.81
" The absolute bioavailability, based on comparisons of area under the serum concentration-time curve values after 200-mg intravenous, 200-mg oral solution, and 200- and 400-mg capsule doses, ranged from 40 to 52%, showing a comparable bioavailability for cefixime at single 200- and 400-mg oral doses."( Pharmacokinetic profile of cefixime in man.
Barone, JS; Faulkner, RD; Kaplan, SA; Silber, BM; Yacobi, A, 1987
)
0.75
" Bioavailability of FK027 after oral dosing was 38% in rats and 47% in dogs, as calculated from intravenous data."( Pharmacokinetics of FK027 in rats and dogs.
Hirose, T; Mine, Y; Sakamoto, H, 1985
)
0.27
" Oral absorption was comparatively slow and bioavailability values for single 5 mg/kg doses were 20."( Clinical pharmacology of cefixime in unweaned calves.
Glickman, A; Lavy, E; Winkler, M; Ziv, G, 1995
)
0.59
"Betalactams, mainly when orally administered, may lead to intestinal flora modifications related to their spectrum of activity, rate of absorption and degradation."( Betalactam therapy and intestinal flora.
Cassetta, MI; Conti, S; Dei, R; Fallani, S; Mazzei, T; Novelli, A, 1995
)
0.29
"Ca2+ channel blockers like nifedipine have been shown to increase the oral bioavailability of beta-lactam antibiotics, such as cefixime, in humans."( PEPT1-mediated cefixime uptake into human intestinal epithelial cells is increased by Ca2+ channel blockers.
Daniel, H; Diestel, S; Kuntz, S; Wenzel, U, 2002
)
0.87
"Utilization of carrier-mediated transport systems in the gastrointestinal tract to increase the bioavailability of drugs is of great interest."( Enhanced intestinal absorption of drugs by activation of peptide transporter PEPT1 using proton-releasing polymer.
Kobayashi, D; Kuruma, K; Nozawa, T; Tamai, I; Toyobuku, H; Tsuji, A, 2003
)
0.32
"This investigation was carried out to evaluate the bioavailability of a new suspension formulation of cefixime (100 mg/5 ml), Winex, relative to the reference product, Suprax (100 mg/5 ml) suspension."( Comparative bioavailability study of cefixime (equivalent to 100 mg/5 ml) suspension (Winex vs Suprax) in healthy male volunteers.
Al-Balla, SA; Al-Khamis, KI; Al-Rashood, KA; Al-Said, MS; Al-Yamani, MJ; Alsarra, IA; Asiri, YA; El-Sayed, YM; Niazy, EM, 2005
)
0.82
"The bioavailability of a new cefixime ((6R,7R)-7-[(Z)-2-(2-amino-4-thiazolyl)-2-(carboxymethoxyimino) acetamido]-8-oxo-3-vinyl-5-thia-1-azabicyclo-[4,2,0]-oct-2-ene-2-carboxylic acid, CAS 79350-37-1) tablet preparation (Loprax) was compared with that of a reference preparation of the drug in 24 healthy male volunteers."( Comparative bioavailability study of two cefixime formulations administered orally in healthy male volunteers.
Islambulchilar, Z; Valizadeh, H; Zakeri-Milani, P, 2008
)
0.9
"This study aimed to evaluate the potential of a novel glycoside non-ionic surfactant synthesized and characterized in our laboratory for increased oral bioavailability of Cefixime."( Glycoside-based niosomal nanocarrier for enhanced in-vivo performance of Cefixime.
Ahmad, F; Ali, I; Elhissi, AM; Imran, M; Nawaz, W; Sadiq, A; Shah, MR; Ullah, F; Ullah, S, 2016
)
0.86
" The most common method to facilitate drug administration in dysphagia patients is to mix the powdered drug with a small amount of thickened water, however little is known about the effects of this method on in vivo bioavailability of drugs."( Do Thickening Agents Used in Dysphagia Diet Affect Drug Bioavailability?
Erdem, ÇE; Eroğlu, H; Eylem, CC; Gökmen-Özel, H; Ilgaz, F; Nemutlu, E; Timur, SS, 2022
)
0.72
"Cefixime; widely employed cephalosporin antibiotic is unfortunately coupled to poor water solubility with resultant low oral bioavailability issues."( Formulation Design, Characterization and
Alotaibi, G; Gul, S; Kamran, M; Khan, MA; Mouslem, AA; Rehman, M; Shafique, M, 2022
)
2.16
"Owing to the significantly improved drug solubility, in vitro release and better antibacterial activity, it can be assumed that CFX-loaded SEDDS might lead to an increased bioavailability and antibacterial activity, possibly leading to improved therapeutic effectiveness."( Enhanced Intestinal Permeability of Cefixime by Self-Emulsifying Drug Delivery System: In-Vitro and Ex-Vivo Characterization.
Aamir, MN; Asim, MH; Ijaz, M; Khan, L; Mahmood, A; Naseem, M; Nazir, I; Rehman, MU; Tahir, MA, 2023
)
1.19
"The utilization of the membrane transport protein PEPT1 as a drug delivery system is a promising strategy to enhance the oral bioavailability of drugs."( Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
Biegel, A; Brandsch, M; Gebauer, S; Hartrodt, B; Neubert, K; Thondorf, I, 2005
)
0.33
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Previous studies using the chinchilla animal model demonstrated that the third generation cephalosporin cefixime (Suprax) with split dosing was as effective as ampicillin in sterilizing the middle ear cleft when infected with S. gonococci. In such cases dosage should be reduced from 400 to 200 mg/day.

ExcerptRelevanceReference
"A comparative study of cefixime (CFIX), a new oral cephem antibiotic, was carried out at the Department of Urology, Nagoya University Hospital and its four affiliated hospitals to evaluate the clinical efficacy and safety of two dosage regimens of CFIX, given either in twice daily doses (BID group) or once daily dose (UID group), in the treatment of acute uncomplicated cystitis."( [Clinical evaluation of usefulness of cefixime (200 mg administered once daily) in the treatment of acute uncomplicated cystitis].
Hattori, R; Ito, Y; Kinukawa, T; Miyake, K; Narushima, M; Obata, K; Otani, T; Sakata, T; Takita, T, 1992
)
0.87
"7 hours) supports the clinical evaluation of a 400mg once-daily dosage regimen for cefixime."( Comparative bioavailability study of cefixime administered as tablets or aqueous solution.
Chassard, D; Frydman, A; Le Liboux, A; Le Roux, Y; Masala, F; Montay, G; Roche, G; Thebault, JJ; Uhlrich, J, 1991
)
0.78
" A daily dosage of 3-6 mg/kg/day was given divided into 2 to 3 times daily for 3-15 days."( [Clinical evaluation of cefixime in pediatric respiratory tract infections].
Iwai, N; Kasai, K; Maki, T; Matsui, Y; Nakamura, H; Ozaki, T; Taneda, Y; Tauchi, N; Yamaguchi, H, 1991
)
0.59
" The dosage was 200 mg bid."( [Cefixime therapy in sinusitis].
Jorde, W; Schata, M, 1990
)
1.19
" The dosage was 2 x 4 mg/kg body weight daily for a period of seven to 11 days."( [Therapy of pediatric infections with cefixime].
Helwig, H, 1990
)
0.55
" The pharmacokinetic profile of cefixime is significantly altered in patients with marked renal impairment (creatinine clearance less than 20 ml/min), and in such cases dosage should be reduced from 400 to 200 mg/day."( [Pharmacokinetic properties of cefixime].
Barré, J, 1989
)
0.85
" Modifications of cefixime kinetics resulting from impaired hepatic function were modest and did not require specific dosage adjustment."( [Effect of hepatic failure upon the pharmacokinetics of cefixime].
Gaudin, C; Lebrec, D; Montay, G; Roche, G; Singlas, E; Taburet, AM, 1989
)
0.86
" Results of these trials demonstrate that cefixime at a dosage of 400 mg once daily is an effective and safe oral antibiotic for the treatment of acute respiratory tract infections."( Comparative, multicenter studies of cefixime and amoxicillin in the treatment of respiratory tract infections.
Johnson, D; Kiani, R; Nelson, B, 1988
)
0.81
"6 h) was slightly longer than that observed after dosing in the fasting condition (3."( The pharmacokinetics of cefixime in the fasted and fed state.
Bohaychuk, W; Desjardins, RE; Faulkner, RD; Haynes, JD; Silber, BM; Yacobi, A, 1988
)
0.58
" Overall, there is no need for any dosage adjustment of the drug in the elderly."( Pharmacokinetics of cefixime in the young and elderly.
Bohaychuk, W; Desjardins, RE; Faulkner, RD; Haynes, JD; Lanc, RA; Silber, BM; Yacobi, A, 1988
)
0.6
"The pharmacokinetics of cefixime (CL 284,635; FK027), a new orally active broad-spectrum cephalosporin, were determined in 26 healthy volunteers, after multiple 200-mg twice-a-day (group 1; N = 13) or 400-mg once-a-day (group 2; N = 13) dosing for 15 days."( Pharmacokinetics of cefixime after once-a-day and twice-a-day dosing to steady state.
Bohaychuk, W; Desjardins, RE; Faulkner, RD; Haynes, JD; Look, ZM; Silber, BM; Weiss, AI, 1987
)
0.9
" In the case of cefixime, single daily doses of 400 mg were taken; with cefaclor, the dosage was 250 mg three times daily."( Bowel flora changes in humans receiving cefixime (CL 284,635) or cefaclor.
Edelstein, MA; Finegold, SM; Gee, R; Ingram-Drake, L; MacDonald, K; Reinhardt, J; Wexler, H, 1987
)
0.89
"25 and 25 mg/kg (each given over 2 hours), approximating the rate of appearance of the drug also given after oral dosing (12."( Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding.
Bialer, M; Look, ZM; Silber, BM; Wu, WH; Yacobi, A, 1987
)
0.6
" In the repeated-dose study, there were mild and transient subjective symptoms such as soft stools, diarrhea, and anorexia, which disappeared without additional treatment during the dosing period."( Phase I study of cefixime, a new oral cephalosporin.
Kanamaru, M; Nakashima, M; Takiguchi, Y; Uematsu, T,
)
0.47
" Upon multiple dosing for 2 weeks on a 400-mg daily or 200-mg twice a day regimen, serum concentrations and urinary recovery of unchanged drug were similar for each group, and there was no drug accumulation."( Pharmacokinetic profile of cefixime in man.
Barone, JS; Faulkner, RD; Kaplan, SA; Silber, BM; Yacobi, A, 1987
)
0.57
" Cefixime was administered daily or twice daily and because results on the two dosage regimens did not differ, data were combined for analysis."( Bacteriologic and clinical efficacy of cefixime compared with amoxicillin in acute otitis media.
Howie, VM; Owen, MJ, 1987
)
1.45
"86 hours and urinary excretions rates up to 12 hours after dosing were 16."( [Clinical studies of cefixime granules in pediatrics].
Chikaoka, H; Kamigaki, M; Koido, R; Matsumoto, K; Nakazawa, S; Narita, A; Niino, K; Sato, H; Suzuki, H, 1986
)
0.59
" The 24-hour urinary and biliary recovery rates of FK027 in rats after oral dosing with 100 mg/kg were 34."( Pharmacokinetics of FK027 in rats and dogs.
Hirose, T; Mine, Y; Sakamoto, H, 1985
)
0.27
"3% after dosing an aqueous solution of cefixime and 35."( Clinical pharmacology of cefixime in unweaned calves.
Glickman, A; Lavy, E; Winkler, M; Ziv, G, 1995
)
0.86
" Cefixime was administered orally in 2 phases at a standard dosage of 5 mg/kg of body weight to clinically normal adult male and female dogs."( Clinical pharmacologic aspects of cefixime in dogs.
Aroch, I; Glickman, A; Lavy, E; Ziv, G, 1995
)
1.48
" In two trials, 891 pediatric patients were enrolled to either cefprozil or amoxicillin-clavulanate dosage regimens."( Multi-investigator evaluation of the efficacy and safety of cefprozil, amoxicillin-clavulanate, cefixime and cefaclor in the treatment of acute otitis media.
Kafetzis, DA, 1994
)
0.51
" Twice daily dosage was preferred with adults (60."( Safety and efficacy of cefixime in treatment of respiratory tract infections in Germany.
Hausen, T; Schmitt, J; Weidlich, G, 1995
)
0.6
" Simulated pediatric dosage regimens and target peak concentrations in the central compartment were as follows: penicillin V-potassium, 26 mg/kg of body weight every 6 h (q6h) and 14 micrograms/ml; cefaclor, 13."( Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model.
Cappelletty, DM; Rybak, MJ, 1996
)
0.54
" All the data have been calculated for the highest recommended oral dosage in France."( Choice of an oral beta-lactam antibiotic for infections due to penicillin-resistant Streptococcus pneumoniae.
Goldstein, FW, 1997
)
0.3
" Group A (n = 41) received cefixime at a dosage of 10 mg/kg to 12 mg/kg per day in two divided doses."( Cefixime: an oral option for the treatment of multidrug-resistant enteric fever in children.
Billoo, AG; Memon, HI; Memon, IA, 1997
)
2.04
"This study compared the efficacy and tolerability of once-daily dosing with either roxithromycin or cefixime in previously healthy adult patients aged between 18 and 60 with markers of uncomplicated community-acquired pneumonia (CAP) in three outpatient clinics in an open, randomized study."( Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia.
Fachinelli, H; Kijanczuk, S; Mingrone, H; Salvarezza, CR, 1998
)
0.8
" The method was found to be reproducible and convenient for quantitative analysis of ceftriaxone, cefixime and cefotaxime in their raw materials and their dosage forms."( HPTLC determination of ceftriaxone, cefixime and cefotaxime in dosage forms.
Agbaba, D; Eric-Jovanovic, S; Vladimirov, S; Zivanov-Stakic, D, 1998
)
0.79
" Middle ear fluid was extracted by tympanocentesis 4, 12 and 24 h after dosing and divided into two fractions: with cells (as collected) (C+) and cell-free (C-)."( Interpretation of middle ear fluid concentrations of antibiotics: comparison between ceftibuten, cefixime and azithromycin.
Arcidiacono, MM; Demartini, G; Dugnani, S; Fraschini, F; Pintucci, JP; Scaglione, F, 1999
)
0.52
"6 microg/ml, respectively with 200 or 400 mg doses of cefditoren pivoxil; plasma concentrations exceed 1 microg/ml for 4 to 6 hours (33-50% of dosing interval)."( Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species.
Beach, ML; Biedenbach, DJ; Johnson, DM; Jones, RN; Pfaller, MA, 2000
)
0.31
" Single doses of each agent were administered and serum concentrations were collected over the standard dosing period of 24 h for all study regimens."( Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens.
Ambrose, PG; Nicolau, DP; Nightingale, CH; Owens, RC; Quintiliani, R; Tessier, P, 2001
)
0.59
" Subsequently, a dosing interval of 6 h was tested in 6 healthy Japanese men, and then 93 Japanese men with gonococcal urethritis were treated with a regimen of two 200-mg doses of cefixime given at a 6-h interval."( Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval.
Deguchi, T; Harada, Y; Ishida, K; Ishihara, S; Ito, M; Kojima, K; Maeda, S; Minamidate, K; Tamaki, M; Tei, K; Yasuda, M; Yokoi, S, 2003
)
0.74
" Simulations based on this model allow the comparison of antibacterial efficacy of different antibiotics and dosing regimens."( Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models.
Derendorf, H; Liu, P; Obermann, B; Rand, KH, 2005
)
0.55
" The results obtained in the analysis of dosage forms agreed well with the contents stated on the labels."( Spectrophotometric, difference spectroscopic, and high-performance liquid chromatographic methods for the determination of cefixime in pharmaceutical formulations.
Pundarikakshudu, K; Shah, PB,
)
0.34
" Although the valproic acid dosage was increased, valproic acid levels did not return to the therapeutic range."( Meropenem -valproic acid interaction in patients with cefepime-associated status epilepticus.
Casteels, M; De Troy, E; Meersseman, W; Spriet, I; Willems, L; Wilmer, A, 2007
)
0.34
"We performed a meta-analysis of randomized controlled trials (RCTs) comparing regimens of the same antibiotic (same dosage and same route of administration) administered for a different time period."( Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis.
Avgeri, SG; Dimopoulos, G; Falagas, ME; Matthaiou, DK; Siempos, II, 2008
)
0.35
"A simple, precise, accurate, and sensitive RP-HPLC method for simultaneous determination of cefixime trihydrate and dicloxacillin sodium in combined tablet dosage form was developed and validated."( Simultaneous determination of cefixime trihydrate and dicloxacillin sodium in pharmaceutical dosage form by reversed-phase high-performance liquid chromatography.
Dhoka, MV; Dumbre, SC; Sandage, SJ,
)
0.64
" The method was successfully applied for the determination of cefixime in pure and dosage form with percent recoveries from 98."( Spectrofluorimetric method for determination and validation of cefixime in pharmaceutical preparations through derivatization with 2-cyanoacetamide.
Jan, MR; Shah, J; Shah, S, 2011
)
0.85
" Absorption correction method and Dual wavelength method were developed for the estimation of Cefixime (CEF) and Erdosteine (ERDO) in capsule dosage form."( Simultaneous estimation of Cefixime and Erdosteine in capsule dosage form by spectrophotometric method.
Dhoka, MV; Gandhi, SV; Gawande, VT; Joshi, PP; Patil, NG, 2009
)
0.87
" BRM-BG demonstrated to be safe and effective as carrier of Cefixime following oral dosing in rabbits."( Glycoside-based niosomal nanocarrier for enhanced in-vivo performance of Cefixime.
Ahmad, F; Ali, I; Elhissi, AM; Imran, M; Nawaz, W; Sadiq, A; Shah, MR; Ullah, F; Ullah, S, 2016
)
0.91
" The pharmacodynamic parameters based on a wide range of concentrations below and above the MIC provide information that could support improving future dosing strategies to treat gonorrhoea."( Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against Neisseria gonorrhoeae.
Althaus, CL; Foerster, S; Hathaway, LJ; Low, N; Unemo, M, 2016
)
0.43
"The EC 50 of the dose-response curves correlated well with Etest MIC values (Pearson's r  = 0."( A new rapid resazurin-based microdilution assay for antimicrobial susceptibility testing of Neisseria gonorrhoeae.
Althaus, CL; Desilvestro, V; Foerster, S; Hathaway, LJ; Unemo, M, 2017
)
0.46
"None of the dosing regimens achieved the target concentration."( A Phase 1 Pharmacokinetic and Safety Study of Extended-Duration, High-dose Cefixime for Cephalosporin-resistant Neisseria gonorrhoeae in the Pharynx.
Barbee, LA; Blumer, JL; Golden, MR; Gray, W; Griffiss, JM; Nayak, SU; OʼRiordan, MA; Zenilman, JM, 2018
)
0.71
"The goal of this study is to assess, by means of pharmacokinetic/pharmacodynamic (PK/PD) analysis using the Monte Carlo simulation, the adequacy of oral cephalosporins cefuroxime axetil, cefixime and cefditoren at different dosing regimens as switch therapy after intravenous cephalosporin treatment in uncomplicated acute pyelonephritis."( Are oral cefuroxime axetil, cefixime and cefditoren pivoxil adequate to treat uncomplicated acute pyelonephritis after switching from intravenous therapy? A pharmacokinetic/pharmacodynamic perspective.
Aguirre-Quiñonero, A; Canut-Blasco, A; Rodríguez-Gascón, A,
)
0.62
"The methodology included: (i) dosing regimen selection and acquisition of pharmacokinetic data; (ii) microbiological data acquisition; and (iii) Monte Carlo simulation to estimate the PTA (probability of PK/PD target attainment) and CFR (cumulative fraction of response), as indicators of treatment success."( Are oral cefuroxime axetil, cefixime and cefditoren pivoxil adequate to treat uncomplicated acute pyelonephritis after switching from intravenous therapy? A pharmacokinetic/pharmacodynamic perspective.
Aguirre-Quiñonero, A; Canut-Blasco, A; Rodríguez-Gascón, A,
)
0.43
" In the present study, Raman spectroscopy has been applied for the identification and quantification of Raman spectral features of cefixime with different concentrations of Active Pharmaceutical Ingredient (API) and excipients in solid dosage forms."( Quantitative analysis of solid dosage forms of cefixime using Raman spectroscopy.
Ahmad, S; Ali, S; Bajwa, J; Bakkar, MA; Bashir, S; Farooq, S; Hussain, AI; Hyat, H; Kashif, M; Majeed, MI; Nawaz, H; Rashid, N, 2020
)
1.02
" The effective parameters on the adsorption process, including solution pH (2-11), salt effect (0-10%), adsorbent dosage (5-50 mg), contact time (5-300 min), and temperature (25-55 °C) were examined."( Nano-Size Biomass Derived from Pomegranate Peel for Enhanced Removal of Cefixime Antibiotic from Aqueous Media: Kinetic, Equilibrium and Thermodynamic Study.
Afzal Kamboh, M; Esmaeili Bidhendi, M; Poursorkh, Z; Rashidi Nodeh, H; Rezania, S; Sereshti, H, 2020
)
0.79
" Data extracted included study year, authors, aim, setting, population, dosing protocols, and outcome results."( Safety of Single-Dose Oral Cefixime, Intramuscular Ceftriaxone, or Intramuscular Gentamicin for the Treatment of Gonorrhea: A Systematic Review and Meta-analysis.
Dresser, J; Wilby, KJ, 2021
)
0.92
"Patients suffering from dysphagia have trouble in swallowing conventional oral dosage forms and there is also risk of choking, which may cause patient noncompliance."( Development and characterization of orodispersible film containing cefixime trihydrate.
Khan, QU; Naeem, M; Rasool, F; Siddique, MI; Usman, M; Zaman, M, 2020
)
0.79
"Swallowing oral solid dosage forms is challenging in patients with dysphagia who are at risk of aspiration or choking."( Do Thickening Agents Used in Dysphagia Diet Affect Drug Bioavailability?
Erdem, ÇE; Eroğlu, H; Eylem, CC; Gökmen-Özel, H; Ilgaz, F; Nemutlu, E; Timur, SS, 2022
)
0.72
" The optimized nano suspension was characterized followed by modification to solidified dosage form."( Formulation Design, Characterization and
Alotaibi, G; Gul, S; Kamran, M; Khan, MA; Mouslem, AA; Rehman, M; Shafique, M, 2022
)
0.72
" Drug concentrations over time will be used to develop mathematical models for optimisation of drug dosing regimens and to estimate pharmacodynamic targets of efficacy."( Optimisation of treatments for oral
Chow, EPF; Fairley, CK; Hammoud, MA; Hocking, JS; Kong, FYS; Landersdorfer, CB; Latch, N; Lewis, DA; Lim, SH; Parker, SL; Roberts, JA; Unemo, M; Wallis, SC; Williamson, DA; Yap, T, 2022
)
0.72
" adipose tissue met the efficacy breakpoint (percentage of the time that free drug concentrations remained above the MIC) for at least 40% of the 8-h dosing interval for organisms with a MIC of 2 mg/liter."( Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
Barbour, A; Derendorf, H; Grant, M; Murthy, B; Sabarinath, SN; Schmidt, S; Seubert, C; Skee, D, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
cephalosporinA class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (34)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency11.91730.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency14.12540.004023.8416100.0000AID485290
Chain A, Beta-lactamaseEscherichia coli K-12Potency1.99530.044717.8581100.0000AID485341
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency19.95260.631035.7641100.0000AID504339
WRNHomo sapiens (human)Potency2.99350.168331.2583100.0000AID651768
GLS proteinHomo sapiens (human)Potency12.58930.35487.935539.8107AID624170
chromobox protein homolog 1Homo sapiens (human)Potency14.12540.006026.168889.1251AID540317
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency26.67950.168316.404067.0158AID720504
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency15.84890.425612.059128.1838AID504891
DNA polymerase eta isoform 1Homo sapiens (human)Potency13.04550.100028.9256213.3130AID588591; AID720502
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency28.81900.050127.073689.1251AID588590; AID720496
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency31.62280.075215.225339.8107AID485360
gemininHomo sapiens (human)Potency0.00460.004611.374133.4983AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency27.43150.031622.3146100.0000AID588579; AID720501
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency70.79466.309660.2008112.2020AID720707
phosphoglycerate kinaseTrypanosoma brucei brucei TREU927Potency3.46180.07578.474229.0628AID602233; AID686980
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency5.87760.060110.745337.9330AID485367; AID504636; AID504637
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency4.46680.003245.467312,589.2998AID2517
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
SUMO-1Homo sapiens (human)IC50 (µMol)34.04000.64707.494715.9000AID624382; AID624383
integrase, partialHuman immunodeficiency virus 1IC50 (µMol)1.82550.07953.52039.9390AID1053171; AID1053172
lens epithelium-derived growth factor p75Homo sapiens (human)IC50 (µMol)1.82550.07953.52039.9390AID1053171; AID1053172
Phospholipase C, gamma 1Homo sapiens (human)IC50 (µMol)1.21201.21203.16626.3720AID743329
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)422.66670.11007.190310.0000AID1443980; AID1449628; AID1473738
Solute carrier family 15 member 1Homo sapiens (human)IC50 (µMol)10,000.00000.18000.19000.2000AID680849
Solute carrier family 15 member 1Homo sapiens (human)Ki8,436.66670.18003.39339.8000AID238858; AID680863; AID681115
Solute carrier family 15 member 2Homo sapiens (human)Ki2,585.20000.79434.22108.0000AID612540
Solute carrier family 15 member 2Rattus norvegicus (Norway rat)Ki7,250.00003.00006.47788.5000AID681114; AID681347
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)89.40002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Apoptotic peptidase activating factor 1Homo sapiens (human)EC50 (µMol)69.69339.080030.293359.0000AID588554; AID588592
caspase-3 isoform a preproproteinHomo sapiens (human)EC50 (µMol)100.00007.89407.89407.8940AID588573
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)AC5017.86004.190012.015018.1100AID720591
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (85)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
monoatomic ion transportSolute carrier family 15 member 2Homo sapiens (human)
protein transportSolute carrier family 15 member 2Homo sapiens (human)
peptide transportSolute carrier family 15 member 2Homo sapiens (human)
peptidoglycan transportSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 15 member 2Homo sapiens (human)
dipeptide transportSolute carrier family 15 member 2Homo sapiens (human)
renal absorptionSolute carrier family 15 member 2Homo sapiens (human)
regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwaySolute carrier family 15 member 2Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
antibacterial innate immune responseSolute carrier family 15 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 15 member 2Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein deacetylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein deacetylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrion organizationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
regulation of ketone biosynthetic processNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
negative regulation of cardiac muscle cell apoptotic processNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
response to nutrient levelsNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein demalonylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
peptidyl-lysine demalonylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein desuccinylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
peptidyl-lysine desuccinylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein deglutarylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
epigenetic regulation of gene expressionNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (39)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
protein bindingSolute carrier family 15 member 2Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 2Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 2Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 2Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
zinc ion bindingNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein-malonyllysine demalonylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein-succinyllysine desuccinylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein-glutaryllysine deglutarylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
NAD+ bindingNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (29)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
phagocytic vesicle membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
membraneSolute carrier family 15 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 15 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
nucleusNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrionNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrial intermembrane spaceNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrial matrixNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
cytosolNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrial matrixNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (356)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID720501qHTS for Inhibitors of Polymerase Kappa: Confirmatory Assay for Cherry-picked Compounds2012PloS one, , Volume: 7, Issue:10
A comprehensive strategy to discover inhibitors of the translesion synthesis DNA polymerase κ.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1211854Unbound biliary clearance in human at 200 mg, po after 24 hrs by T-tube method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID486733Antimicrobial activity against Enterococcus faecalis after 24 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and antimicrobial activity of cholic acid hydrazone analogues.
AID1184217Antibacterial activity against Escherichia coli ATCC 15224 at 40 mg/mL after 24 hrs by disc diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Potentially bioactive organotin(IV) compounds: synthesis, characterization, in vitro bioactivities and interaction with SS-DNA.
AID641636Antibacterial activity against Salmonella typhi ATCC 6539 at 1 mg/ml after 24 hrs by agar well diffusion method2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Electrochemical and spectroscopic investigations of isoniazide and its analogs with ds.DNA at physiological pH: evaluation of biological activities.
AID530832Oral bioavailability in Neisseria gonorrhoeae infected patient at 400 mg, po2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID525545Antimicrobial activity against Haemophilus influenzae Rd KW20 by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.
AID530843Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 8 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID588104Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring PBP2 XXXIV pattern, MAST 51 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID279564Antimicrobial activity against Haemophilus influenzae BLPACR strains2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.
AID279563Antimicrobial activity against Haemophilus influenzae BLNAR strains2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.
AID510070Antimicrobial activity against Neisseria gonorrhoeae isolate NG0201 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID588119Antimicrobial activity against Neisseria gonorrhoeae clinical isolates after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID530838Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 3 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID586079Antimicrobial activity against multidrug-resistant Neisseria gonorrhoeae isolates harboring mosaic penicillin-binding protein 2 penA by Etest2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Characteristics and dissemination of mosaic penicillin-binding protein 2-harboring multidrug-resistant Neisseria gonorrhoeae isolates with reduced cephalosporin susceptibility in northern Taiwan.
AID588110Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring porB G120K, A121D mutant gene, PBP2 XXXVIII pattern, deletion of nucleotide A from mtrA promoter, MAST 3158 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID1556569Potentiation of cefixime-mediated antibacterial activity against methicillin resistant Staphylococcus aureus N315 assessed as cefixime MIC incubated for 24 hrs by two fold serial dilution method (Rvb = 31.52 10'-3 mM)2019European journal of medicinal chemistry, Oct-01, Volume: 179A new exploration towards aminothiazolquinolone oximes as potentially multi-targeting antibacterial agents: Design, synthesis and evaluation acting on microbes, DNA, HSA and topoisomerase IV.
AID510087Antimicrobial activity against Neisseria gonorrhoeae isolate NG0513 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID486731Antimicrobial activity against Enterobacter aerogenes after 24 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and antimicrobial activity of cholic acid hydrazone analogues.
AID612540Binding affinity to human PepT2 in SKTP cells2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping.
AID1377973Antibacterial activity against Klebsiella pneumoniae ATCC 13882 measured after overnight incubation by two-fold serial dilution method2017European journal of medicinal chemistry, Sep-29, Volume: 138Antibiofilm potential of 16-oxo-cleroda-3, 13(14) E-diene-15 oic acid and its five new γ-amino γ-lactone derivatives against methicillin resistant Staphylococcus aureus and Streptococcus mutans.
AID405301Antibacterial activity against beta-lactamase nonproducing ampicillin susceptible Haemophilus influenzae isolate by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID732765Antibacterial activity against Bacillus subtilis assessed as growth inhibition at 37 degC after overnight incubation by agar well diffusion method2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and pharmacological evaluation of some novel 2-(5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles.
AID588115Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring PBP2 XXXVIII pattern, deletion of nucleotide A from mtrA promoter, MAST 3553 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID405316Antibacterial activity against Haemophilus influenzae group IIc isolates with ftsI gene mutation by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID510060Antimicrobial activity against Neisseria gonorrhoeae isolate NG9911 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID549203Antimicrobial activity against Pseudomonas aeruginosa after 24 hrs by ELISA2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Post Groebke-Blackburn multicomponent protocol: synthesis of new polyfunctional imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine derivatives as potential antimicrobial agents.
AID405302Antibacterial activity against beta-lactamase positive ampicillin resistant Haemophilus influenzae isolate by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID486730Antimicrobial activity against Pseudomonas aeruginosa after 24 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and antimicrobial activity of cholic acid hydrazone analogues.
AID324847Antimicrobial activity against Neisseria gonorrhoeae 82 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID732769Antibacterial activity against Escherichia coli assessed as diameter of growth inhibition zone at 2 mg/ml at 37 degC after 24 hrs by agar well diffusion method2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and pharmacological evaluation of some novel 2-(5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID535763Antimicrobial activity against penicillin-producing Neisseria gonorrhoeae NGON 06-041 expressing beta-lactamase TEM-1, MLST type ST-1588 and MAST type ST-4012 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Identification of TEM-135 beta-lactamase in penicillinase-producing Neisseria gonorrhoeae strains in Japan.
AID561807fAUC in plasma of healthy human at 400 mg, po by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID405317Antibacterial activity against Haemophilus influenzae group IId isolates with ftsI gene mutation by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID732760Antibacterial activity against Pseudomonas aeruginosa assessed as growth inhibition at 37 degC after overnight incubation by agar well diffusion method2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and pharmacological evaluation of some novel 2-(5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID680857TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 20 uM, Cefixime: 10000 uM) in PEPT1-expressing HeLa cells1997Biochimica et biophysica acta, Mar-13, Volume: 1324, Issue:2
Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2.
AID530846Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 2469 isolate 11 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1377970Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 measured after overnight incubation by two-fold serial dilution method2017European journal of medicinal chemistry, Sep-29, Volume: 138Antibiofilm potential of 16-oxo-cleroda-3, 13(14) E-diene-15 oic acid and its five new γ-amino γ-lactone derivatives against methicillin resistant Staphylococcus aureus and Streptococcus mutans.
AID732773Antibacterial activity against Staphylococcus aureus assessed as diameter of growth inhibition zone at 2 mg/ml at 37 degC after 24 hrs by agar well diffusion method2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and pharmacological evaluation of some novel 2-(5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1184221Antibacterial activity against Bordetella bronchiseptica ATCC 4617 at 40 mg/mL after 24 hrs by disc diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Potentially bioactive organotin(IV) compounds: synthesis, characterization, in vitro bioactivities and interaction with SS-DNA.
AID535759Antimicrobial activity against penicillin-producing Neisseria gonorrhoeae NGON 00-002 expressing beta-lactamase TEM-1, MLST type ST-1590 and MAST type ST-270 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Identification of TEM-135 beta-lactamase in penicillinase-producing Neisseria gonorrhoeae strains in Japan.
AID681115TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in Caco-2 cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID238858Binding affinity against membrane transport protein PEPT1 in human Caco-2 cells2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
AID510088Antimicrobial activity against Neisseria gonorrhoeae isolate NG0514 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID510077Antimicrobial activity against Neisseria gonorrhoeae isolate NG0311 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID1184219Antibacterial activity against Enterobacter aerogenes ATCC 13048 at 40 mg/mL after 24 hrs by disc diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Potentially bioactive organotin(IV) compounds: synthesis, characterization, in vitro bioactivities and interaction with SS-DNA.
AID732770Antibacterial activity against Klebsiella aerogenes assessed as diameter of growth inhibition zone at 2 mg/ml at 37 degC after 24 hrs by agar well diffusion method2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and pharmacological evaluation of some novel 2-(5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles.
AID324848Antimicrobial activity against Neisseria gonorrhoeae 90 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1211834Total biliary clearance in human at 200 mg, po after 24 hrs by T-tube method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID732763Antibacterial activity against Klebsiella aerogenes assessed as growth inhibition at 37 degC after overnight incubation by agar well diffusion method2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and pharmacological evaluation of some novel 2-(5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles.
AID279559Antimicrobial activity against Haemophilus influenzae strains causing clinical infections2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.
AID1377972Antibiofilm activity against methicillin-resistant Staphylococcus aureus ATCC 43300 measured after overnight incubation by crystal violet-staining based assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Antibiofilm potential of 16-oxo-cleroda-3, 13(14) E-diene-15 oic acid and its five new γ-amino γ-lactone derivatives against methicillin resistant Staphylococcus aureus and Streptococcus mutans.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID486734Antimicrobial activity against Bacillus megaterium after 24 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and antimicrobial activity of cholic acid hydrazone analogues.
AID510086Antimicrobial activity against Neisseria gonorrhoeae isolate NG0512 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID595731Antimicrobial activity against Enterobacter aerogenes after 24 hrs by broth microdilution method2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Design, synthesis and in vitro antimicrobial evaluation of novel Imidazo[1,2-a]pyridine and imidazo[2,1-b][1,3]benzothiazole motifs.
AID1211870Total biliary clearance in iv dosed rat2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID530842Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 7 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID510059Antimicrobial activity against Neisseria gonorrhoeae isolate NG9812 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID530841Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 6 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID405308Antibacterial activity against beta-lactamase positive ampicillin resistant Haemophilus influenzae isolate assessed as percent resistant isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID535640Antimicrobial activity against Group B streptococcus serotype Ib C2 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID495749Antimicrobial activity against Salmonella enterica serotype Virchow 3464b by Etest method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID549205Antimicrobial activity against Staphylococcus aureus after 24 hrs by ELISA2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Post Groebke-Blackburn multicomponent protocol: synthesis of new polyfunctional imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine derivatives as potential antimicrobial agents.
AID1211802Drug excretion in iv dosed rat assessed as compound excreted into bile2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1377975Antibiofilm activity against Proteus mirabilis ATCC 12453 measured after overnight incubation by crystal violet-staining based assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Antibiofilm potential of 16-oxo-cleroda-3, 13(14) E-diene-15 oic acid and its five new γ-amino γ-lactone derivatives against methicillin resistant Staphylococcus aureus and Streptococcus mutans.
AID510067Antimicrobial activity against Neisseria gonorrhoeae isolate NG0109 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID1602086Antibacterial activity against Pseudomonas aeruginosa clinical isolates measured after overnight incubation2019European journal of medicinal chemistry, Mar-15, Volume: 166Design, synthesis and anti-bacterial studies of piperazine derivatives against drug resistant bacteria.
AID1377968Antibiofilm activity against Streptococcus mutans ATCC 25175 measured after overnight incubation by crystal violet-staining based assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Antibiofilm potential of 16-oxo-cleroda-3, 13(14) E-diene-15 oic acid and its five new γ-amino γ-lactone derivatives against methicillin resistant Staphylococcus aureus and Streptococcus mutans.
AID369634Antimicrobial activity against Haemophilus influenzae expressing mutant ftsI gene2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?
AID510082Antimicrobial activity against Neisseria gonorrhoeae isolate NG0503 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID510071Antimicrobial activity against Neisseria gonorrhoeae isolate NG0204 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID641634Antibacterial activity against Bordetella bronchiseptica ATCC 10580 at 1 mg/ml after 24 hrs by agar well diffusion method2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Electrochemical and spectroscopic investigations of isoniazide and its analogs with ds.DNA at physiological pH: evaluation of biological activities.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID324840Antimicrobial activity against Neisseria gonorrhoeae 196 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID510057Antimicrobial activity against Neisseria gonorrhoeae isolate NG9806 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID324838Antimicrobial activity against Neisseria gonorrhoeae 253 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID1377959Bactericidal activity against Streptococcus mutans ATCC 25175 measured after overnight incubation2017European journal of medicinal chemistry, Sep-29, Volume: 138Antibiofilm potential of 16-oxo-cleroda-3, 13(14) E-diene-15 oic acid and its five new γ-amino γ-lactone derivatives against methicillin resistant Staphylococcus aureus and Streptococcus mutans.
AID510065Antimicrobial activity against Neisseria gonorrhoeae isolate NG0003 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID510073Antimicrobial activity against Neisseria gonorrhoeae isolate NG0206 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID510078Antimicrobial activity against Neisseria gonorrhoeae isolate NG0312 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID681114TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in SKPT cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID510090Antimicrobial activity against Neisseria gonorrhoeae isolate NG0402 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID535643Antimicrobial activity against Group B streptococcus serotype III N3 by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID588105Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring porB G120K, A121D mutant gene, PBP1 L421P mutant gene, PBP2 XXXVIII pattern, deletion of nucleotide A from mtrA promoter, MAST 3563 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID324837Antimicrobial activity against Neisseria gonorrhoeae 201 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID525546Antimicrobial activity against Haemophilus influenzae Rd KW20 harboring with plasmid pB1000 bearing beta-lactamase ROB-1 by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.
AID588113Antimicrobial activity against Neisseria gonorrhoeae clinical isolates assessed as percent resistant isolates after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID588106Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring porB A121S mutant gene, PBP1 L421P mutant gene, PBP2 XXXVIII pattern, deletion of nucleotide A from mtrA promoter, MAST 3116 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID588116Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring PBP1 L421P mutant gene, PBP2 XXXVII pattern, deletion of nucleotide A from mtrA promoter, MtrR G45D mutant MAST 299 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID560048Antibacterial activity against Neisseria gonorrhoeae isolate SM1 expressing SF-A mosaic penA allele by agar dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California.
AID405313Antibacterial activity against Haemophilus influenzae group I isolates with ftsI gene mutation by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID525549Antimicrobial activity against ampicillin resistant nontypeable Haemophilus influenzae isolate BB1052 harboring with plasmid pB1000 bearing beta-lactamase ROB-1 by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.
AID510075Antimicrobial activity against Neisseria gonorrhoeae isolate NG0303 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID495753Antimicrobial activity against Escherichia coli J5 transconjugants expressing beta lactamase CTX-M-9 isolated from human flora associated C3H rat infected with Salmonella enterica serotype Virchow and treated with Cefixime-cluvulanic acid by Etest method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID324839Antimicrobial activity against Neisseria gonorrhoeae 273 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID682283TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.02 uM, Cefixime: 2500 uM) in OCTN2-expressing HeLa cells2000The Journal of biological chemistry, Jan-21, Volume: 275, Issue:3
beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.
AID561806AUC in plasma of healthy human at 400 mg, po by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID405312Antibacterial activity against beta-lactamase producing amoxicillin-clavulanic acid-resistant Haemophilus influenzae isolate assessed as percent resistant isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID405307Antibacterial activity against beta-lactamase positive ampicillin resistant Haemophilus influenzae isolate assessed as percent susceptible isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID324845Antimicrobial activity against Neisseria gonorrhoeae 59 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID588107Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring porB G120K, A121D mutant gene, PBP1 L421P mutant gene, PBP2 XXXVIII pattern, deletion of nucleotide A from mtrA promoter, MAST 3158 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID680863TP_TRANSPORTER: inhibition of Cefadroxil uptake in Caco-2 cells1996The Journal of pharmacology and experimental therapeutics, May, Volume: 277, Issue:2
Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells.
AID1556572Potentiation of fluconazole-mediated antifungal activity against Candida albicans assessed as fluconazole MIC incubated for 24 hrs by two fold serial dilution method (Rvb = 13.06 10'-3 mM)2019European journal of medicinal chemistry, Oct-01, Volume: 179A new exploration towards aminothiazolquinolone oximes as potentially multi-targeting antibacterial agents: Design, synthesis and evaluation acting on microbes, DNA, HSA and topoisomerase IV.
AID510095Antimicrobial activity against Neisseria gonorrhoeae isolate NG0202 expressing chromosomal cefixime-resistant penA gene at 0.031 ug/ml after 16 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID530833Cmax in Neisseria gonorrhoeae infected patient at 400 mg, po2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID535634Antimicrobial activity against Group B streptococcus serotype VI R6 harboring F395L, V405A, R433H, H438Y, A374V and G648A mutations in PBP 2X and T567I mutation in PBP 2B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID405303Antibacterial activity against beta-lactamase nonproducing ampicillin resistant Haemophilus influenzae isolate by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1602084Antibacterial activity against Streptococcus hemolyticus clinical isolates measured after overnight incubation2019European journal of medicinal chemistry, Mar-15, Volume: 166Design, synthesis and anti-bacterial studies of piperazine derivatives against drug resistant bacteria.
AID1180939Antibacterial activity against Proteus vulgaris NCIM-2027 after 24 hrs by broth dilution method2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Structure-guided discovery of 1,3,5-triazine-pyrazole conjugates as antibacterial and antibiofilm agent against pathogens causing human diseases with favorable metabolic fate.
AID495750Antimicrobial activity against Escherichia coli J5 by Etest method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID595733Antimicrobial activity against Enterococcus faecalis after 24 hrs by broth microdilution method2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Design, synthesis and in vitro antimicrobial evaluation of novel Imidazo[1,2-a]pyridine and imidazo[2,1-b][1,3]benzothiazole motifs.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID405304Antibacterial activity against beta-lactamase producing amoxicillin-clavulanic acid-resistant Haemophilus influenzae isolate by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID681152TP_TRANSPORTER: uptake in Xenopus laevis oocytes2002Drug metabolism and pharmacokinetics, , Volume: 17, Issue:4
Transporter-mediated Drug Interactions.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1556573Potentiation of fluconazole-mediated antifungal activity against Candida tropicalis assessed as fluconazole MIC incubated for 24 hrs by two fold serial dilution method (Rvb = 26.12 10'-3 mM)2019European journal of medicinal chemistry, Oct-01, Volume: 179A new exploration towards aminothiazolquinolone oximes as potentially multi-targeting antibacterial agents: Design, synthesis and evaluation acting on microbes, DNA, HSA and topoisomerase IV.
AID588108Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring porB G120K, A121D mutant gene, PBP1 L421P mutant gene, PBP2 XXXVIII pattern, insertion of nucleotide T from mtrA promoter, MAST 3158 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID324849Antimicrobial activity against Neisseria gonorrhoeae 91 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID279562Antimicrobial activity against Haemophilus influenzae BLPAR strains2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.
AID486729Antimicrobial activity against Escherichia coli after 24 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and antimicrobial activity of cholic acid hydrazone analogues.
AID1527490Antimicrobial activity against Pseudomonas aeruginosa NCIM-2036 after 24 hrs by CLSI based broth dilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Structure-activity relationships (SAR) of triazine derivatives: Promising antimicrobial agents.
AID405314Antibacterial activity against Haemophilus influenzae group IIa isolates with ftsI gene mutation by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID732767Antibacterial activity against Pseudomonas aeruginosa assessed as diameter of growth inhibition zone at 2 mg/ml at 37 degC after 24 hrs by agar well diffusion method2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and pharmacological evaluation of some novel 2-(5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1377974Antibiofilm activity against Klebsiella pneumoniae ATCC 13882 measured after overnight incubation by crystal violet-staining based assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Antibiofilm potential of 16-oxo-cleroda-3, 13(14) E-diene-15 oic acid and its five new γ-amino γ-lactone derivatives against methicillin resistant Staphylococcus aureus and Streptococcus mutans.
AID732762Antibacterial activity against Escherichia coli assessed as growth inhibition at 37 degC after overnight incubation by agar well diffusion method2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and pharmacological evaluation of some novel 2-(5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles.
AID549202Antimicrobial activity against Escherichia coli after 24 hrs by ELISA2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Post Groebke-Blackburn multicomponent protocol: synthesis of new polyfunctional imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine derivatives as potential antimicrobial agents.
AID560050Antibacterial activity against Neisseria gonorrhoeae isolate SM3 expressing SF-A mosaic penA allele by agar dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California.
AID588111Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring porB G120K, A121D mutant gene, PBP1 L421P mutant gene, PBP2 XXXIV pattern, deletion of nucleotide A from mtrA promoter, MAST 225 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID535766Antimicrobial activity against penicillin-producing Neisseria gonorrhoeae NGON 08-043 expressing beta-lactamase TEM-1, MLST type ST-7823 and MAST type ST-1288 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Identification of TEM-135 beta-lactamase in penicillinase-producing Neisseria gonorrhoeae strains in Japan.
AID679555TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 50 uM, Cefixime: 10000 uM) in PEPT2-expressing HeLa cells1997Biochimica et biophysica acta, Mar-13, Volume: 1324, Issue:2
Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2.
AID510058Antimicrobial activity against Neisseria gonorrhoeae isolate NG9811 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID535761Antimicrobial activity against penicillin-producing Neisseria gonorrhoeae NGON 04-025 expressing beta-lactamase TEM-135, MLST type ST-1597 and MAST type ST-1549 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Identification of TEM-135 beta-lactamase in penicillinase-producing Neisseria gonorrhoeae strains in Japan.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID529756Antibacterial activity against Beta-lactamase negative ampicillin-resistant Haemophilus influenzae isolate with SSN motif mutation after 20 to 24 hrs by disk diffusion method using <=29 mm disk2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID405305Antibacterial activity against beta-lactamase nonproducing ampicillin susceptible Haemophilus influenzae isolate assessed as percent susceptible isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID510069Antimicrobial activity against Neisseria gonorrhoeae isolate NG0111 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID549207Antimicrobial activity against Bacillus megaterium after 24 hrs by ELISA2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Post Groebke-Blackburn multicomponent protocol: synthesis of new polyfunctional imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine derivatives as potential antimicrobial agents.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID495751Antimicrobial activity against Escherichia coli J5 transconjugants expressing beta lactamase CTX-M-9 isolated from human flora associated C3H rat infected with Salmonella enterica serotype Virchow by Etest method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID595730Antimicrobial activity against Pseudomonas aeruginosa after 24 hrs by broth microdilution method2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Design, synthesis and in vitro antimicrobial evaluation of novel Imidazo[1,2-a]pyridine and imidazo[2,1-b][1,3]benzothiazole motifs.
AID405315Antibacterial activity against Haemophilus influenzae group IIb isolates with ftsI gene mutation by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID405318Antibacterial activity against Haemophilus influenzae group III-like isolates with ftsI gene mutation by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID530845Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 10 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID586080Antimicrobial activity against Neisseria gonorrhoeae isolates harboring non-mosaic penicillin-binding protein 2 penA by Etest2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Characteristics and dissemination of mosaic penicillin-binding protein 2-harboring multidrug-resistant Neisseria gonorrhoeae isolates with reduced cephalosporin susceptibility in northern Taiwan.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID530844Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 9 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID510085Antimicrobial activity against Neisseria gonorrhoeae isolate NG0511 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID510066Antimicrobial activity against Neisseria gonorrhoeae isolate NG0008 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID324841Antimicrobial activity against Neisseria gonorrhoeae 30 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID510063Antimicrobial activity against Neisseria gonorrhoeae isolate NG9914 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID1602079Antibacterial activity against Bacillus subtilis ATCC 6633 measured after overnight incubation2019European journal of medicinal chemistry, Mar-15, Volume: 166Design, synthesis and anti-bacterial studies of piperazine derivatives against drug resistant bacteria.
AID510081Antimicrobial activity against Neisseria gonorrhoeae isolate NG0410 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID535765Antimicrobial activity against penicillin-producing Neisseria gonorrhoeae NGON 08-041 expressing beta-lactamase TEM-1, MLST type ST-1584 and MAST type ST-1478 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Identification of TEM-135 beta-lactamase in penicillinase-producing Neisseria gonorrhoeae strains in Japan.
AID530839Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 4 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID510079Antimicrobial activity against Neisseria gonorrhoeae isolate NG0401 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID1602085Antibacterial activity against Escherichia coli clinical isolates measured after overnight incubation2019European journal of medicinal chemistry, Mar-15, Volume: 166Design, synthesis and anti-bacterial studies of piperazine derivatives against drug resistant bacteria.
AID679796TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 5 uM) in SKPT cells1997Biochimica et biophysica acta, Mar-13, Volume: 1324, Issue:2
Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1180938Antibacterial activity against Bacillus cereus NCIM-2156 after 24 hrs by broth dilution method2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Structure-guided discovery of 1,3,5-triazine-pyrazole conjugates as antibacterial and antibiofilm agent against pathogens causing human diseases with favorable metabolic fate.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID535760Antimicrobial activity against penicillin-producing Neisseria gonorrhoeae NGON 00-027 expressing beta-lactamase TEM-1, MLST type ST-1921 and MAST type ST-1817 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Identification of TEM-135 beta-lactamase in penicillinase-producing Neisseria gonorrhoeae strains in Japan.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1180937Antibacterial activity against Staphylococcus aureus NCIM-2079 after 24 hrs by broth dilution method2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Structure-guided discovery of 1,3,5-triazine-pyrazole conjugates as antibacterial and antibiofilm agent against pathogens causing human diseases with favorable metabolic fate.
AID279560Antimicrobial activity against Haemophilus influenzae strains that are normal flora2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.
AID510068Antimicrobial activity against Neisseria gonorrhoeae isolate NG0110 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID324844Antimicrobial activity against Neisseria gonorrhoeae 67 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID510092Antimicrobial activity against Neisseria gonorrhoeae isolate NGON03-092 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID324846Antimicrobial activity against Neisseria gonorrhoeae 35 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID588118Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring porB G120K, A121D mutant gene, PBP2 XXXVI pattern, deletion of nucleotide A from mtrA promoter, MAST 3596 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID588109Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring PBP2 XXXV pattern, deletion of nucleotide A from mtrA promoter, MAST 546 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID656363Plasma protein binding in human2011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.
AID732766Antibacterial activity against Staphylococcus aureus assessed as growth inhibition at 37 degC after overnight incubation by agar well diffusion method2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and pharmacological evaluation of some novel 2-(5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID549204Antimicrobial activity against Enterobacter aerogenes after 24 hrs by ELISA2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Post Groebke-Blackburn multicomponent protocol: synthesis of new polyfunctional imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine derivatives as potential antimicrobial agents.
AID535646Antimicrobial activity against Group B Streptococcus serotype III NEM 316 by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID1377963Bactericidal activity against Proteus mirabilis ATCC 12453 measured after overnight incubation2017European journal of medicinal chemistry, Sep-29, Volume: 138Antibiofilm potential of 16-oxo-cleroda-3, 13(14) E-diene-15 oic acid and its five new γ-amino γ-lactone derivatives against methicillin resistant Staphylococcus aureus and Streptococcus mutans.
AID732768Antibacterial activity against Proteus mirabilis assessed as diameter of growth inhibition zone at 2 mg/ml at 37 degC after 24 hrs by agar well diffusion method2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and pharmacological evaluation of some novel 2-(5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID510064Antimicrobial activity against Neisseria gonorrhoeae isolate NG0002 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID1211878Unbound biliary clearance in iv dosed rat2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID535641Antimicrobial activity against Group B streptococcus serotype V C1 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID405306Antibacterial activity against beta-lactamase nonproducing ampicillin susceptible Haemophilus influenzae isolate assessed as percent resistant isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID535635Antimicrobial activity against Group B streptococcus serotype VI R5 harboring F395L, V405A, R433H, H438Y, and G648A mutations in PBP 2X and T567I mutation in PBP 2B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588114Antimicrobial activity against Neisseria gonorrhoeae clinical isolates assessed as percent susceptible isolates after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID510091Antimicrobial activity against Neisseria gonorrhoeae isolate NGON03-079 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID1377967Antibacterial activity against Streptococcus mutans ATCC 25175 measured after overnight incubation by two-fold serial dilution method2017European journal of medicinal chemistry, Sep-29, Volume: 138Antibiofilm potential of 16-oxo-cleroda-3, 13(14) E-diene-15 oic acid and its five new γ-amino γ-lactone derivatives against methicillin resistant Staphylococcus aureus and Streptococcus mutans.
AID680849TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 5 uM) in Caco-2 cells1997Biochimica et biophysica acta, Mar-13, Volume: 1324, Issue:2
Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1556571Potentiation of cefixime-mediated antibacterial activity against Klebsiella pneumoniae assessed as cefixime MIC incubated for 24 hrs by two fold serial dilution method (Rvb = 15.76 10'-3 mM)2019European journal of medicinal chemistry, Oct-01, Volume: 179A new exploration towards aminothiazolquinolone oximes as potentially multi-targeting antibacterial agents: Design, synthesis and evaluation acting on microbes, DNA, HSA and topoisomerase IV.
AID1556570Potentiation of cefixime-mediated antibacterial activity against Staphylococcus aureus assessed as cefixime MIC incubated for 24 hrs by two fold serial dilution method (Rvb = 31.52 10'-3 mM)2019European journal of medicinal chemistry, Oct-01, Volume: 179A new exploration towards aminothiazolquinolone oximes as potentially multi-targeting antibacterial agents: Design, synthesis and evaluation acting on microbes, DNA, HSA and topoisomerase IV.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID510080Antimicrobial activity against Neisseria gonorrhoeae isolate NG0404 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID588117Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring porB G120K, A121D mutant gene, PBP1 L421P mutant gene, PBP2 XXXVIII pattern, deletion of nucleotide A from mtrA promoter, MAST 3570 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID1602080Antibacterial activity against Escherichia coli ATCC 25922 measured after overnight incubation2019European journal of medicinal chemistry, Mar-15, Volume: 166Design, synthesis and anti-bacterial studies of piperazine derivatives against drug resistant bacteria.
AID561809Ratio of fAUC in muscle to fAUC in plasma of healthy human at 400 mg, po by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID641637Antibacterial activity against Escherichia coli ATCC 15224 at 1 mg/ml after 24 hrs by agar well diffusion method2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Electrochemical and spectroscopic investigations of isoniazide and its analogs with ds.DNA at physiological pH: evaluation of biological activities.
AID641638Antibacterial activity against Micrococcus luteus ATCC 10240 at 1 mg/ml after 24 hrs by agar well diffusion method2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Electrochemical and spectroscopic investigations of isoniazide and its analogs with ds.DNA at physiological pH: evaluation of biological activities.
AID510062Antimicrobial activity against Neisseria gonorrhoeae isolate NG9913 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID560052Antibacterial activity against Neisseria gonorrhoeae isolate SM5 expressing SF-B mosaic penA allele by agar dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California.
AID641639Antibacterial activity against Staphylococcus aureus ATCC 6538 at 1 mg/ml after 24 hrs by agar well diffusion method2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Electrochemical and spectroscopic investigations of isoniazide and its analogs with ds.DNA at physiological pH: evaluation of biological activities.
AID560049Antibacterial activity against Neisseria gonorrhoeae isolate SM2 expressing SF-A mosaic penA allele by agar dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID495748Antimicrobial activity against Escherichia coli ATCC 25922 by Etest method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID1180941Antibacterial activity against Pseudomonas aeruginosa NCIM-2036 after 24 hrs by broth dilution method2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Structure-guided discovery of 1,3,5-triazine-pyrazole conjugates as antibacterial and antibiofilm agent against pathogens causing human diseases with favorable metabolic fate.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID681350TP_TRANSPORTER: inhibition of Gly-Sar uptake in PEPT1-expressing LLC-PK1 cells1997The American journal of physiology, 11, Volume: 273, Issue:5
Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID530835Protein binding in Neisseria gonorrhoeae infected patient serum at 400 mg, po2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID549206Antimicrobial activity against Enterococcus faecalis after 24 hrs by ELISA2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Post Groebke-Blackburn multicomponent protocol: synthesis of new polyfunctional imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine derivatives as potential antimicrobial agents.
AID510089Antimicrobial activity against Neisseria gonorrhoeae isolate NG0202 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID530837Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 2 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID405311Antibacterial activity against beta-lactamase producing amoxicillin-clavulanic acid-resistant Haemophilus influenzae isolate assessed as percent susceptible isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID732761Antibacterial activity against Proteus mirabilis assessed as growth inhibition at 37 degC after overnight incubation by agar well diffusion method2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and pharmacological evaluation of some novel 2-(5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles.
AID1377969Antibacterial activity against Proteus mirabilis ATCC 12453 measured after overnight incubation by two-fold serial dilution method2017European journal of medicinal chemistry, Sep-29, Volume: 138Antibiofilm potential of 16-oxo-cleroda-3, 13(14) E-diene-15 oic acid and its five new γ-amino γ-lactone derivatives against methicillin resistant Staphylococcus aureus and Streptococcus mutans.
AID529755Antibacterial activity against Beta-lactamase negative ampicillin-resistant Haemophilus influenzae isolate with SSN motif mutation after 20 to 24 hrs by Etest method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1377971Bactericidal activity against methicillin-resistant Staphylococcus aureus ATCC 43300 measured after overnight incubation2017European journal of medicinal chemistry, Sep-29, Volume: 138Antibiofilm potential of 16-oxo-cleroda-3, 13(14) E-diene-15 oic acid and its five new γ-amino γ-lactone derivatives against methicillin resistant Staphylococcus aureus and Streptococcus mutans.
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID535636Antimicrobial activity against Group B streptococcus serotype VI R4 harboring Q557E mutation in PBP 2X and T567I, Y262N mutations in PBP 2B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID324835Antimicrobial activity against Neisseria gonorrhoeae 158 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID279561Antimicrobial activity against Haemophilus influenzae BLNAS strains2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.
AID535637Antimicrobial activity against Group B streptococcus serotype Ib R3 harboring Q557E, A400V mutations in PBP 2X and T567I, G539E mutations in PBP 2B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID1527484Antimicrobial activity against Escherichia coli NCIM-2065 assessed as reduction in microbial growth after 24 hrs by CLSI based broth dilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Structure-activity relationships (SAR) of triazine derivatives: Promising antimicrobial agents.
AID560770Antibacterial activity against Neisseria gonorrhoeae isolate SW1 expressing nonmosaic penA allele by agar dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California.
AID535639Antimicrobial activity against Group B streptococcus serotype VI R1 harboring F395L, V405A, R433H, H438Y, and G648A mutations in PBP 2X and T567I mutation in PBP 2B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID535632Antimicrobial activity against Group B streptococcus R8 harboring T77I, S353F and A514V in PBP 2X; V80A and G613R in PBP 2B; and L45P, N163K, N723S and G527V in PBP 1A by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID535644Antimicrobial activity against Group B streptococcus serotype Ib N2 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID560051Antibacterial activity against Neisseria gonorrhoeae isolate SM4 expressing SF-B mosaic penA allele by agar dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California.
AID535638Antimicrobial activity against Group B streptococcus serotype VI R2 harboring F395L, V405A, R433H, H438Y, and G648A mutations in PBP 2X and T567I mutation in PBP 2B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID510074Antimicrobial activity against Neisseria gonorrhoeae isolate NG0207 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID586084Antimicrobial activity against multidrug-resistant Neisseria gonorrhoeae isolates by Etest2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Characteristics and dissemination of mosaic penicillin-binding protein 2-harboring multidrug-resistant Neisseria gonorrhoeae isolates with reduced cephalosporin susceptibility in northern Taiwan.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID530834Half life in Neisseria gonorrhoeae infected patient at 400 mg, po2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID641635Antibacterial activity against Enterobacter aerogenes ATCC 13048 at 1 mg/ml after 24 hrs by agar well diffusion method2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Electrochemical and spectroscopic investigations of isoniazide and its analogs with ds.DNA at physiological pH: evaluation of biological activities.
AID510083Antimicrobial activity against Neisseria gonorrhoeae isolate NG0508 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID595732Antimicrobial activity against Staphylococcus aureus after 24 hrs by broth microdilution method2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Design, synthesis and in vitro antimicrobial evaluation of novel Imidazo[1,2-a]pyridine and imidazo[2,1-b][1,3]benzothiazole motifs.
AID1184218Antibacterial activity against Staphylococcus aureus ATCC 6538 at 40 mg/mL after 24 hrs by disc diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Potentially bioactive organotin(IV) compounds: synthesis, characterization, in vitro bioactivities and interaction with SS-DNA.
AID324842Antimicrobial activity against Neisseria gonorrhoeae 64 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID405310Antibacterial activity against beta-lactamase nonproducing ampicillin resistant Haemophilus influenzae isolate assessed as percent resistant isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID535768Antimicrobial activity against penicillin-producing Neisseria gonorrhoeae NGON 08-046 expressing beta-lactamase TEM-1, MLST type ST-1584 and MAST type ST-1478 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Identification of TEM-135 beta-lactamase in penicillinase-producing Neisseria gonorrhoeae strains in Japan.
AID561808fAUC in muscle of healthy human at 400 mg, po by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID525547Antimicrobial activity against ampicillin resistant nontypeable Haemophilus influenzae isolate BB1050 harboring with plasmid pB1000 bearing beta-lactamase ROB-1 by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.
AID324834Antimicrobial activity against Neisseria gonorrhoeae 119 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID597167Antimicrobial activity against Escherichia coli after 24 hrs by broth microdilution method2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Design, synthesis and in vitro antimicrobial evaluation of novel Imidazo[1,2-a]pyridine and imidazo[2,1-b][1,3]benzothiazole motifs.
AID560771Antibacterial activity against Neisseria gonorrhoeae isolate SW2 expressing nonmosaic penA allele by agar dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California.
AID1180940Antibacterial activity against Escherichia coli NCIM-2065 after 24 hrs by broth dilution method2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Structure-guided discovery of 1,3,5-triazine-pyrazole conjugates as antibacterial and antibiofilm agent against pathogens causing human diseases with favorable metabolic fate.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID535767Antimicrobial activity against penicillin-producing Neisseria gonorrhoeae NGON 08-044 expressing beta-lactamase TEM-1, MLST type ST-7823 and MAST type ST-1288 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Identification of TEM-135 beta-lactamase in penicillinase-producing Neisseria gonorrhoeae strains in Japan.
AID510061Antimicrobial activity against Neisseria gonorrhoeae isolate NG9912 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID732771Antibacterial activity against Staphylococcus epidermidis assessed as diameter of growth inhibition zone at 2 mg/ml at 37 degC after 24 hrs by agar well diffusion method2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and pharmacological evaluation of some novel 2-(5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles.
AID530840Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 5 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1184222Antibacterial activity against Bacillus subtilis ATCC 6633 at 40 mg/mL after 24 hrs by disc diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Potentially bioactive organotin(IV) compounds: synthesis, characterization, in vitro bioactivities and interaction with SS-DNA.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID324850Antimicrobial activity against Neisseria gonorrhoeae 128 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID679879TP_TRANSPORTER: inhibition of Ceftibuten uptake (Ceftibuten: 1000 uM, Cefixime: 10000 uM) in PEPT1-expressing LLC-PK1 cells1997The Journal of pharmacology and experimental therapeutics, Jun, Volume: 281, Issue:3
Characterization of stably transfected kidney epithelial cell line expressing rat H+/peptide cotransporter PEPT1: localization of PEPT1 and transport of beta-lactam antibiotics.
AID595734Antimicrobial activity against Bacillus megaterium after 24 hrs by broth microdilution method2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Design, synthesis and in vitro antimicrobial evaluation of novel Imidazo[1,2-a]pyridine and imidazo[2,1-b][1,3]benzothiazole motifs.
AID525550Antimicrobial activity against ampicillin resistant serotype-e Haemophilus influenzae isolate BB1053 harboring with plasmid pB1000 bearing beta-lactamase ROB-1 by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.
AID1211815Drug excretion in human assessed as compound excreted into bile at 200 mg, po after 24 hrs by T-tube method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID529754Antibacterial activity against Beta-lactamase negative ampicillin-resistant Haemophilus influenzae isolate with SSN motif mutation after 20 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID495752Antimicrobial activity against Escherichia coli J5 transconjugants expressing beta lactamase CTX-M-9 isolated from human flora associated C3H rat infected with Salmonella enterica serotype Virchow and treated with Cefixime by Etest method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID525548Antimicrobial activity against ampicillin resistant nontypeable Haemophilus influenzae isolate BB1051 harboring with plasmid pB1000 bearing beta-lactamase ROB-1 by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.
AID405309Antibacterial activity against beta-lactamase nonproducing ampicillin resistant Haemophilus influenzae isolate assessed as percent susceptible isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID510096Antimicrobial activity against Neisseria gonorrhoeae isolate NG0003 expressing chromosomal cefixime-resistant penA gene at 0.31 ug/ml after 16 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID535762Antimicrobial activity against penicillin-producing Neisseria gonorrhoeae NGON 05-042 expressing beta-lactamase TEM-1, MLST type ST-1588 and MAST type ST-4012 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Identification of TEM-135 beta-lactamase in penicillinase-producing Neisseria gonorrhoeae strains in Japan.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID535633Antimicrobial activity against Group B streptococcus serotype Ia R7 harboring T77I, F395V and S353F in PBP 2X; V80A and G613R in PBP 2B; and L45P, N163K, N723S and Y470F in PBP 1A by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID679326TP_TRANSPORTER: uptake in Xenopus laevis oocytes1997The Journal of pharmacy and pharmacology, Aug, Volume: 49, Issue:8
The predominant contribution of oligopeptide transporter PepT1 to intestinal absorption of beta-lactam antibiotics in the rat small intestine.
AID510094Antimicrobial activity against Neisseria gonorrhoeae isolate NGON07-002 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID510084Antimicrobial activity against Neisseria gonorrhoeae isolate NG0509 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID681347TP_TRANSPORTER: inhibition of Gly-Sar uptake in PEPT2-expressing LLC-PK1 cells1997The American journal of physiology, 11, Volume: 273, Issue:5
Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.
AID535642Antimicrobial activity against Group B streptococcus serotype VI N4 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID510093Antimicrobial activity against Neisseria gonorrhoeae isolate NGON03-115 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID535647Antimicrobial activity against Group B Streptococcus serotype V 2603 V/R harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID409942Inhibition of human recombinant MAOA by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1180936Antibacterial activity against Bacillus subtilis NCIM-2063 after 24 hrs by broth dilution method2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Structure-guided discovery of 1,3,5-triazine-pyrazole conjugates as antibacterial and antibiofilm agent against pathogens causing human diseases with favorable metabolic fate.
AID324836Antimicrobial activity against Neisseria gonorrhoeae 188 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID732764Antibacterial activity against Staphylococcus epidermidis assessed as growth inhibition at 37 degC after overnight incubation by agar well diffusion method2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and pharmacological evaluation of some novel 2-(5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles.
AID510072Antimicrobial activity against Neisseria gonorrhoeae isolate NG0205 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID510076Antimicrobial activity against Neisseria gonorrhoeae isolate NG0304 expressing chromosomal cefixime-resistant penA gene by agar dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
AID732772Antibacterial activity against Bacillus subtilis assessed as diameter of growth inhibition zone at 2 mg/ml at 37 degC after 24 hrs by agar well diffusion method2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and pharmacological evaluation of some novel 2-(5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles.
AID486732Antimicrobial activity against Staphylococcus aureus after 24 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and antimicrobial activity of cholic acid hydrazone analogues.
AID530836Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 1 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID535764Antimicrobial activity against penicillin-producing Neisseria gonorrhoeae NGON 08-003 expressing beta-lactamase TEM-135, MLST type ST-7823 and MAST type ST-4013 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Identification of TEM-135 beta-lactamase in penicillinase-producing Neisseria gonorrhoeae strains in Japan.
AID1527481Antimicrobial activity against Proteus vulgaris NCIM-2027 assessed as reduction in microbial growth after 24 hrs by CLSI based broth dilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Structure-activity relationships (SAR) of triazine derivatives: Promising antimicrobial agents.
AID535645Antimicrobial activity against Group B Streptococcus serotype Ia N1 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID1602081Antibacterial activity against Pseudomonas aeruginosa ATCC 15442 measured after overnight incubation2019European journal of medicinal chemistry, Mar-15, Volume: 166Design, synthesis and anti-bacterial studies of piperazine derivatives against drug resistant bacteria.
AID324843Antimicrobial activity against Neisseria gonorrhoeae 65 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1184220Antibacterial activity against Salmonella typhimurium ATCC 14028 at 40 mg/mL after 24 hrs by disc diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Potentially bioactive organotin(IV) compounds: synthesis, characterization, in vitro bioactivities and interaction with SS-DNA.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (859)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990135 (15.72)18.7374
1990's258 (30.03)18.2507
2000's136 (15.83)29.6817
2010's210 (24.45)24.3611
2020's120 (13.97)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 123.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index123.39 (24.57)
Research Supply Index6.95 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index230.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (123.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials175 (20.21%)5.53%
Trials1 (1.72%)5.53%
Trials0 (0.00%)5.53%
Reviews57 (6.58%)6.00%
Reviews2 (3.45%)6.00%
Reviews0 (0.00%)6.00%
Case Studies61 (7.04%)4.05%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational8 (0.92%)0.25%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other565 (65.24%)84.16%
Other55 (94.83%)84.16%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (28)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Azithromycin and Cefixime Combination Versus Azithromycin Alone for the Out-patient Treatment of Clinically Suspected or Confirmed Uncomplicated Typhoid Fever in South Asia; a Randomised Controlled Trial [NCT04349826]Phase 41,500 participants (Anticipated)Interventional2021-05-23Recruiting
Trial Evaluating the Clinical Efficacy of Cefixime for Treatment of Early Syphilis in Non-pregnant Women [NCT03752112]Phase 1/Phase 2180 participants (Anticipated)Interventional2019-11-22Recruiting
Introduction of Nitrofurantoin in Place of Ciprofloxacin in Patients of Uncomplicated Urinary Tract Infection: a Controlled Clinical Trial to Establish the Relationship Between Revival and Associated Shift in Sensitivity Pattern of the Causative Microbes [NCT03716804]Phase 462 participants (Actual)Interventional2018-06-06Completed
Clinical Trial Comparing the Effectiveness of Cefixime Versus Penicillin G for Treatment of Early Syphilis [NCT04958122]Phase 3400 participants (Anticipated)Interventional2021-06-20Recruiting
Comparison of Efficacy of Two Combination Regimens for the Treatment of Uncomplicated Neisseria Gonorrhoeae and Chlamydia Trachomatis Coinfection [NCT05216744]Phase 2125 participants (Actual)Interventional2021-07-15Completed
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Efficacy of the Application of Moxifloxacin and Cefixime in Reduction of Inflammatory Sequelae and Complications After Mandibular Third Molar Surgery [NCT05027893]157 participants (Actual)Interventional2019-06-07Active, not recruiting
Typhoid Fever: Combined vs. Single Antibiotic Therapy. A Prospective Randomized Controlled Study in Nepal. [NCT02224040]Phase 4120 participants (Anticipated)Interventional2013-08-31Recruiting
Is Combination Antibiotic Therapy Superior to Monotherapy in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease [NCT04879030]Phase 2/Phase 3170 participants (Actual)Interventional2020-01-01Completed
"Performance of HPV DNA Test in Presence of Co-infection With Common RTIs" [NCT02830230]508 participants (Anticipated)Interventional2016-07-31Not yet recruiting
An Open-label, Randomised, Single-dose, Two-period Cross-over Study to Evaluate Bioequivalence of SKF101804 Cefixime 400 mg Capsule Versus Cefixime 400 mg Capsule Reference Product in Healthy Adult Participants Under Fasting Conditions [NCT03329547]Phase 10 participants (Actual)Interventional2018-01-11Withdrawn(stopped due to Change in commercial strategy)
Clinical Trial Evaluating the Clinical Efficacy of Cefixime for Treatment of Early Syphilis [NCT03660488]Phase 258 participants (Actual)Interventional2018-09-03Completed
Efficacy of Empirical Ciprofloxacin Plus Metronidazole and Cefixime Plus Metronidazole Therapy for the Treatment of Liver Abscess: A Randomised Controlled Clinical Trial [NCT03969758]Phase 3140 participants (Anticipated)Interventional2019-07-31Not yet recruiting
Cefixime 800 mg Plus Doxycycline 100 mg b.i.d. for 7 Days Compared to Ceftriaxone 1 g Plus Azithromycin 2 g for Treatment of Urogenital, Rectal and Pharyngeal Gonorrhoea: A Randomised Controlled Trial [NCT06090565]Phase 4161 participants (Actual)Interventional2021-04-01Completed
A Phase One Study of Intravenous Irinotecan and Bortezomib in Children With Recurrent/Refractory High-Risk Neuroblastoma [NCT00644696]Phase 118 participants (Actual)Interventional2008-04-30Completed
Experimental Human Infection With Isogenic Mutants of Neisseria Gonorrhoeae [NCT03840811]Phase 127 participants (Actual)Interventional2017-04-23Completed
A Pilot Study of the Addition of Bevacizumab to Vincristine, Oral Irinotecan, and Temozolomide (VOIT Regimen) for Relapsed/Refractory Pediatric Solid Tumors [NCT00786669]Phase 113 participants (Actual)Interventional2008-10-31Completed
The Pharmacokinetics of Extended Duration High-Dose Cefixime Co-administered With Azithromycin for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study [NCT02708992]Phase 110 participants (Actual)Interventional2016-04-28Completed
The Pharmacokinetics of Extended Duration High-Dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study [NCT01949363]Phase 125 participants (Actual)Interventional2013-12-31Completed
A Phase I/II Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors [NCT02596503]Phase 12 participants (Actual)Interventional2015-10-21Completed
A Phase I Trial of a Live, Genetically Modified Salmonella Typhimurium (VNP20009) for the Treatment of Cancer by Intratumoral Injection [NCT00004216]Phase 10 participants Interventional1999-08-31Completed
A Phase I Study Of Oral Irinotecan, Temozolomide, Cefixime In Children With Recurrent/Resistant High-Risk Neuroblastoma [NCT00093353]Phase 130 participants (Anticipated)Interventional2004-05-31Completed
A Phase I Study of ZD1839 (Iressa) in Combination With Irinotecan (Camptosar or CPT-11) and Vincristine in Pediatric Patients With Refractory Solid Tumors [NCT00186979]Phase 134 participants (Actual)Interventional2003-05-31Completed
Division of Microbiology and Infectious Diseases, (DMID) 21-0018: Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae [NCT05294588]Phase 2140 participants (Anticipated)Interventional2022-04-18Recruiting
"Targeted Clinical Trials to Reduce the Risk of Antimicrobial Resistance The SCOUT Study: Short Course Therapy for Urinary Tract Infections in Children" [NCT01595529]Phase 2717 participants (Actual)Interventional2012-05-18Completed
Bioequivalence Study of Cefixime Trihydrate 100 mg/5 mL DS in Indonesia Healthy Volunteers [NCT04982861]22 participants (Actual)Interventional2020-06-15Completed
A Randomized Trial to Evaluate the Need for Empiric Therapy for Mucopurulent Cervicitis of Unknown Etiology [NCT01072136]Phase 387 participants (Actual)Interventional2010-03-31Terminated
Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract [NCT02021006]Phase 3292 participants (Actual)Interventional2013-12-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01072136 (8) [back to overview]Determine Pelvic Inflammatory Disease (PID) in Patients Empirically Treated With Cefixime and Azithromycin for Mucopurulent Cervicitis (MPC) in Comparison to no Treatment.
NCT01072136 (8) [back to overview]Evaluate Clinical Cure in Participants Not Treated Versus Participants Empirically Treated With Cefixime and Azithromycin for Mucopurulent Cervicitis (MPC).
NCT01072136 (8) [back to overview]Evaluate Microbiological Cure of Mycoplasma Genitalium in Women Treated With Cefixime and Azithromycin Versus Placebo.
NCT01072136 (8) [back to overview]Examine Adverse Events in Patients Empirically Treated With Cefixime and Azithromycin for Mucopurulent Cervicitis (MPC) in Comparison to no Treatment.
NCT01072136 (8) [back to overview]Determine the Clinical Cure, Partial Response and Failure Proportions for Mucopurulent Cervicitis at 2 Months for Each Study Arm.
NCT01072136 (8) [back to overview]Determine the Clinical Cure, Partial Response and Failure Proportions for Mucopurulent Cervicitis at 2-3 Weeks for Each Study Arm.
NCT01072136 (8) [back to overview]Explore the Role of Bacterial Vaginosis (BV) in Persistent Mucopurulent Cervicitis (MPC).
NCT01072136 (8) [back to overview]Explore the Role of Mycoplasma Genitalium in Persistent Mucopurulent Cervicitis (MPC).
NCT01595529 (12) [back to overview]Comparison of Efficacy Based on Symptomatic Urinary Tract Infection (UTI) Between Short-course and Standard-course of Antibiotics.
NCT01595529 (12) [back to overview]Comparison of Efficacy Based on Symptomatic Urinary Tract Infection (UTI) Between Short-course and Standard-course of Antibiotics. Per-protocol Population.
NCT01595529 (12) [back to overview]Comparison of Number of Subjects That Have a Recurrent Infection (Includes a Relapse UTI or a Reinfection) Following Short-course Versus Standard-course of Antibiotics.
NCT01595529 (12) [back to overview]Comparison of Number of Subjects That Have a Recurrent Infection (Includes a Relapse UTI or a Reinfection) Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population.
NCT01595529 (12) [back to overview]Comparison of the Number of Subjects With Asymptomatic Bacteriuria Following Short-course Versus Standard-course of Antibiotics.
NCT01595529 (12) [back to overview]Comparison of the Number of Subjects With Asymptomatic Bacteriuria Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population.
NCT01595529 (12) [back to overview]Comparison of the Number of Subjects With Clinical Symptoms That May be Related to a UTI Following Short-course Versus Standard-course of Antibiotics.
NCT01595529 (12) [back to overview]Comparison of the Number of Subjects With Clinical Symptoms That May be Related to a UTI Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population
NCT01595529 (12) [back to overview]Comparison of the Number of Subjects With Positive Urine Cultures Following Short-course Versus Standard-course of Antibiotics.
NCT01595529 (12) [back to overview]Comparison of the Number of Subjects With Positive Urine Cultures Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population.
NCT01595529 (12) [back to overview]Comparison of the Number of Subjects That Become Colonized With Antimicrobial Resistant E. Coli and K. Pneumoniae in the Gastrointestinal Tract Following Short-course Versus Standard Course of Antibiotics. Per-protocol Population.
NCT01595529 (12) [back to overview]Comparison of the Number of Subjects That Become Colonized With Antimicrobial Resistant Escherichia Coli (E. Coli) and Klebsiella Pneumoniae (K. Pneumoniae) in the Gastrointestinal Tract Following Short-course Versus Standard Course of Antibiotics.
NCT03660488 (1) [back to overview]Treatment Response
NCT03840811 (7) [back to overview]Median Time From Inoculation to Treatment Among Infected Participants by Day 6, by Strain, in Non-competitive Infections
NCT03840811 (7) [back to overview]Proportion of Participants That Become Infected as Defined by a Positive Urine or Urethral Swab Culture Among Infections Initiated With Individual N. Gonorrhoeae Strains in Non-competitive Infections
NCT03840811 (7) [back to overview]Proportion of Participants That Become Infected as Defined by a Positive Urine or Urethral Swab Culture for Infections Initiated With Mixed Inocula
NCT03840811 (7) [back to overview]Proportion of Participants With Occurrence of Bacteriuria in Non-competitive Infections, by Strain
NCT03840811 (7) [back to overview]Proportion of Participants With Occurrence of Signs and Symptoms of Urethritis Attributable to Gonococcal Infection in Non-competitive Infections, by Strain
NCT03840811 (7) [back to overview]Proportion of Participants With Occurrence of Urethritis in Non-competitive Infections
NCT03840811 (7) [back to overview]The Competitive Index of the Mutant Compared to Wild Type Proportion of Organisms With the Predicted Competitive Advantage Recovered From Urine and/or Urethral Swab Specimens From Infected Participants

Determine Pelvic Inflammatory Disease (PID) in Patients Empirically Treated With Cefixime and Azithromycin for Mucopurulent Cervicitis (MPC) in Comparison to no Treatment.

The number of participants experiencing PID after randomization. (NCT01072136)
Timeframe: At 2-3 week and 2 month (Day 50-70) follow-up.

Interventionparticipants (Number)
Azithromycin/Cefixime1
Placebo0

[back to top]

Evaluate Clinical Cure in Participants Not Treated Versus Participants Empirically Treated With Cefixime and Azithromycin for Mucopurulent Cervicitis (MPC).

The proportion of participants who have cleared MPC by the second follow-up visit. Clinical cure is defined as: absence of cervical mucopus and absence of easily induced cervical bleeding and < 30 white blood cells per oil immersion field on cervical gram stain. (NCT01072136)
Timeframe: Visit 2 - 2 months (Day 50-70).

Interventionpercentage of participants (Number)
Azithromycin/Cefixime19
Placebo33

[back to top]

Evaluate Microbiological Cure of Mycoplasma Genitalium in Women Treated With Cefixime and Azithromycin Versus Placebo.

The proportion of participants with mycoplasma genitalium at baseline who clear mycoplasma genitalium in either the vagina or cervix at their last follow-up visit. (NCT01072136)
Timeframe: At 2-3 weeks and 2 month (Day 50-70) follow-up.

Interventionparticipants (Number)
Azithromycin/Cefixime2
Placebo1

[back to top]

Examine Adverse Events in Patients Empirically Treated With Cefixime and Azithromycin for Mucopurulent Cervicitis (MPC) in Comparison to no Treatment.

The proportion of participants experiencing one or more adverse events after randomization. (NCT01072136)
Timeframe: At 2-3 week and 2 month (Day 50-70) follow-up.

Interventionpercentage of participants (Number)
Azithromycin/Cefixime36.4
Placebo27.9

[back to top]

Determine the Clinical Cure, Partial Response and Failure Proportions for Mucopurulent Cervicitis at 2 Months for Each Study Arm.

"Clinical Failure:~Persistent cervical mucopus and/or easily induced cervical bleeding, and the presence of > 30 WBCs per oil immersion field on cervical gram stain OR~Signs of pelvic inflammatory disease, including cervical motion tenderness, uterine tenderness or adnexal tenderness.~Partial Response:~Persistent cervical mucopus and/or easily induced cervical bleeding and <30 WBCs per oil immersion field on cervical gram stain OR~The presence of ≥ 30 WBCs per oil immersion field on cervical gram stain in the absence of both cervical mucopus and easily induced cervical bleeding.~Clinical Cure:~• Absence of cervical mucopus and absence of easily induced cervical bleeding and < 30 WBC's per oil immersion field on cervical gram stain." (NCT01072136)
Timeframe: At 2 month ( Day 50-70) follow-up.

,
Interventionpercentage of participants (Number)
Clinical curePartial responseClinical failure
Azithromycin/Cefixime194338
Placebo335017

[back to top]

Determine the Clinical Cure, Partial Response and Failure Proportions for Mucopurulent Cervicitis at 2-3 Weeks for Each Study Arm.

"Clinical Failure:~Persistent cervical mucopus and/or easily induced cervical bleeding, and the presence of > 30 WBCs per oil immersion field on cervical gram stain OR~Signs of pelvic inflammatory disease, including cervical motion tenderness, uterine tenderness or adnexal tenderness.~Partial Response:~Persistent cervical mucopus and/or easily induced cervical bleeding and <30 WBCs per oil immersion field on cervical gram stain OR~The presence of ≥ 30 WBCs per oil immersion field on cervical gram stain in the absence of both cervical mucopus and easily induced cervical bleeding.~Clinical Cure:~• Absence of cervical mucopus and absence of easily induced cervical bleeding and < 30 WBC's per oil immersion field on cervical gram stain." (NCT01072136)
Timeframe: At 2-3 weeks follow-up.

,
Interventionpercentage of participants (Number)
Clinical curePartial responseClinical failure
Azithromycin/Cefixime74152
Placebo07228

[back to top]

Explore the Role of Bacterial Vaginosis (BV) in Persistent Mucopurulent Cervicitis (MPC).

"Proportion of participants with clinical failure, partial response, or clinical cure for mucopurulent cervicitis at 2 month follow-up according to asymptomatic bacterial vaginosis status at 2 month follow-up.~Clinical Failure:~Persistent cervical mucopus and/or easily induced cervical bleeding, and the presence of > 30 WBCs per oil immersion field on cervical gram stain OR~Signs of pelvic inflammatory disease, including cervical motion tenderness, uterine tenderness or adnexal tenderness.~Partial Response:~Persistent cervical mucopus and/or easily induced cervical bleeding and <30 WBCs per oil immersion field on cervical gram stain OR~The presence of ≥ 30 WBCs per oil immersion field on cervical gram stain in the absence of both cervical mucopus and easily induced cervical bleeding.~Clinical Cure:~• Absence of cervical mucopus and absence of easily induced cervical bleeding and < 30 WBC's per oil immersion field on cervical gram stain." (NCT01072136)
Timeframe: At 2 month (Day 50-70) follow-up.

,,
Interventionpercentage of participants (Number)
No Asymptomatic Bacterial VaginosisAsymptomatic Bacterial Vaginosis
Clinical Cure4357
Clinical Failure7822
Partial Response8813

[back to top]

Explore the Role of Mycoplasma Genitalium in Persistent Mucopurulent Cervicitis (MPC).

"Proportion of participants with clinical failure, partial response, or clinical cure for mucopurulent cervicitis at 2 months according to mycoplasma genitalium status(positive cervical or vaginal swabs versus both negative) at 2 months.~Clinical Failure:~Persistent cervical mucopus and/or easily induced cervical bleeding, and the presence of > 30 WBCs per oil immersion field on cervical gram stain OR~Signs of pelvic inflammatory disease, including cervical motion tenderness, uterine tenderness or adnexal tenderness.~Partial Response:~Persistent cervical mucopus and/or easily induced cervical bleeding and <30 WBCs per oil immersion field on cervical gram stain OR~The presence of ≥ 30 WBCs per oil immersion field on cervical gram stain in the absence of both cervical mucopus and easily induced cervical bleeding.~Clinical Cure:~• Absence of cervical mucopus and absence of easily induced cervical bleeding and < 30 WBC's per oil immersion field on cervical gram stain." (NCT01072136)
Timeframe: At 2 month (Day 50-70) follow-up.

,,
Interventionpercentage of participants (Number)
Negative for mycoplasma genitaliumPositive for mycoplasma genitalium
Clinical Cure1000
Clinical Failure1000
Partial Response946

[back to top]

Comparison of Efficacy Based on Symptomatic Urinary Tract Infection (UTI) Between Short-course and Standard-course of Antibiotics.

"A subject will be categorized as a treatment failure, if he/she has a symptomatic UTI in period between Day 6 through the Day 11 - 14 Test of Cure (TOC) Visit:~Symptoms~Symptoms for all subjects (ages two months to 10 years): fever (a documented temperature of at least 100.4 °F OR 38°C measured anywhere on the body) ,dysuria~Additional symptoms for subjects > 2 years of age: suprapubic, abdominal, or flank pain or tenderness OR urinary urgency, frequency, or hesitancy (defined as an increase in these symptoms from pre-diagnosis conditions)~Additional symptoms for subjects = 2 months to 2 years of age: poor feeding OR vomiting AND~Pyuria on urinalysis AND~Culture proven infection with a single uropathogen NOTE: As per the above criteria, asymptomatic subjects (including subjects assessed as having asymptomatic bacteriuria) at the Day 11-14 TOC visit will NOT be considered a treatment failure for the primary outcome measure." (NCT01595529)
Timeframe: Day 11 through Day 14

InterventionParticipants (Count of Participants)
Standard Course Treatment2
Short Course Treatment14

[back to top]

Comparison of Efficacy Based on Symptomatic Urinary Tract Infection (UTI) Between Short-course and Standard-course of Antibiotics. Per-protocol Population.

"A subject will be categorized as a treatment failure, if he/she has a symptomatic UTI in period between Day 6 through the Day 11 - 14 Test of Cure (TOC) Visit:~Symptoms~Symptoms for all subjects (ages two months to 10 years): fever (a documented temperature of at least 100.4 °F OR 38°C measured anywhere on the body) ,dysuria~Additional symptoms for subjects > 2 years of age: suprapubic, abdominal, or flank pain or tenderness OR urinary urgency, frequency, or hesitancy (defined as an increase in these symptoms from pre-diagnosis conditions)~Additional symptoms for subjects = 2 months to 2 years of age: poor feeding OR vomiting AND~Pyuria on urinalysis AND~Culture proven infection with a single uropathogen NOTE: As per the above criteria, asymptomatic subjects (including subjects assessed as having asymptomatic bacteriuria) at the Day 11-14 TOC visit will NOT be considered a treatment failure for the primary outcome measure." (NCT01595529)
Timeframe: Day 11 through Day 14

InterventionParticipants (Count of Participants)
Standard Course Treatment2
Short Course Treatment9

[back to top]

Comparison of Number of Subjects That Have a Recurrent Infection (Includes a Relapse UTI or a Reinfection) Following Short-course Versus Standard-course of Antibiotics.

(NCT01595529)
Timeframe: Day 11 through Day 44

InterventionParticipants (Count of Participants)
Standard Course Treatment12
Short Course Treatment13

[back to top]

Comparison of Number of Subjects That Have a Recurrent Infection (Includes a Relapse UTI or a Reinfection) Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population.

(NCT01595529)
Timeframe: Day 11 through Day 44

InterventionParticipants (Count of Participants)
Standard Course Treatment10
Short Course Treatment13

[back to top]

Comparison of the Number of Subjects With Asymptomatic Bacteriuria Following Short-course Versus Standard-course of Antibiotics.

"Asymptomatic Bacteriuria is defined in any SCOUT subject by:~Absence of symptoms attributable to UTI including fever AND/OR the following:~Symptoms for all children (ages two months to 10 years):~fever (a documented temperature of at least 100.4 °F OR 38°C measured anywhere on the body)~dysuria~Additional symptoms for children > 2 years of age:~suprapubic, abdominal, or flank pain or tenderness OR~urinary urgency, frequency, or hesitancy (defined as an increase in these symptoms from pre-diagnosis conditions)~Additional symptoms for children = 2 months to 2 years of age:~poor feeding OR~vomiting AND~A positive urine culture~5 x 104 CFU/mL (catheterized or suprapubic aspiration urine specimen) OR~>105 CFU/mL (clean void specimen)." (NCT01595529)
Timeframe: Day 11 through Day 14

InterventionParticipants (Count of Participants)
Standard Course Treatment11
Short Course Treatment29

[back to top]

Comparison of the Number of Subjects With Asymptomatic Bacteriuria Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population.

"Asymptomatic Bacteriuria is defined in any SCOUT subject by:~Absence of symptoms attributable to UTI including fever AND/OR the following:~Symptoms for all children (ages two months to 10 years):~fever (a documented temperature of at least 100.4 °F OR 38°C measured anywhere on the body)~dysuria~Additional symptoms for children > 2 years of age:~suprapubic, abdominal, or flank pain or tenderness OR~urinary urgency, frequency, or hesitancy (defined as an increase in these symptoms from pre-diagnosis conditions)~Additional symptoms for children = 2 months to 2 years of age:~poor feeding OR~vomiting AND~A positive urine culture~5 x 104 CFU/mL (catheterized or suprapubic aspiration urine specimen) OR~>105 CFU/mL (clean void specimen)." (NCT01595529)
Timeframe: Day 11 through Day 14

InterventionParticipants (Count of Participants)
Standard Course Treatment11
Short Course Treatment29

[back to top] [back to top] [back to top]

Comparison of the Number of Subjects With Positive Urine Cultures Following Short-course Versus Standard-course of Antibiotics.

(NCT01595529)
Timeframe: Up to Day 14

InterventionParticipants (Count of Participants)
Standard Course Treatment6
Short Course Treatment41

[back to top]

Comparison of the Number of Subjects With Positive Urine Cultures Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population.

(NCT01595529)
Timeframe: Up to Day 14

InterventionParticipants (Count of Participants)
Standard Course Treatment6
Short Course Treatment35

[back to top]

Comparison of the Number of Subjects That Become Colonized With Antimicrobial Resistant E. Coli and K. Pneumoniae in the Gastrointestinal Tract Following Short-course Versus Standard Course of Antibiotics. Per-protocol Population.

"A child would have emergent antibiotic resistance if they:~Had no antibiotic-resistant E.coli or K.pneumoniae at enrollment but one or both are now present. OR~Had either antibiotic-resistant E.coli or K.pneumoniae at enrollment but now the other antibiotic-resistant organism is present OR~Had antibiotic-resistant E.coli and/or K.pneumoniae at enrollment, but have now developed resistance to new antibiotics in either organism." (NCT01595529)
Timeframe: Day 11 through Day 30

,
InterventionParticipants (Count of Participants)
Test of Cure Visit (Day 11-14)Outcome Assessment Visit (Day 24-30)
Short Course Treatment2823
Standard Course Treatment2223

[back to top]

Comparison of the Number of Subjects That Become Colonized With Antimicrobial Resistant Escherichia Coli (E. Coli) and Klebsiella Pneumoniae (K. Pneumoniae) in the Gastrointestinal Tract Following Short-course Versus Standard Course of Antibiotics.

"A child would have emergent antibiotic resistance if they:~Had no antibiotic-resistant E.coli or K.pneumoniae at enrollment but one or both are now present. OR~Had either antibiotic-resistant E.coli or K.pneumoniae at enrollment but now the other antibiotic-resistant organism is present OR~Had antibiotic-resistant E.coli and/or K.pneumoniae at enrollment, but have now developed resistance to new antibiotics in either organism." (NCT01595529)
Timeframe: Day 11 through Day 30

,
InterventionParticipants (Count of Participants)
Test of Cure Visit (Day 11-14)Outcome Assessment Visit (Day 24-30)
Short Course Treatment3128
Standard Course Treatment2223

[back to top]

Treatment Response

subjects who have a 4-fold decrease (from study entry Rapid plasma reagin) in Rapid plasma reagintiters from baseline at 3 or 6 months will be considered a positive treatment response. (NCT03660488)
Timeframe: 3 or 6 months after treatment completion

InterventionParticipants (Count of Participants)
Benzathine Penicillin G14
Cefixime Group13

[back to top]

Median Time From Inoculation to Treatment Among Infected Participants by Day 6, by Strain, in Non-competitive Infections

The median time from inoculation to antibiotic treatment were calculated for each group. (NCT03840811)
Timeframe: Day 2 through the day of treatment, up to Day 6

Interventiondays (Median)
Mutant FA75373.0
Wild-type FA10903.0

[back to top]

Proportion of Participants That Become Infected as Defined by a Positive Urine or Urethral Swab Culture Among Infections Initiated With Individual N. Gonorrhoeae Strains in Non-competitive Infections

Infection is defined by a positive urine or urethral swab culture. The proportion of infected participants by Day 6 with N. gonorrhoeae was assessed in each trial by group among participants with non-competitive infections. Participants could become infected and received treatment any day before or on day 6. (NCT03840811)
Timeframe: day of infection, any day between Day 2 and Day 6

Interventionproportion of participants (Number)
Mutant FA75370.86
Wild-type FA10901.00

[back to top]

Proportion of Participants That Become Infected as Defined by a Positive Urine or Urethral Swab Culture for Infections Initiated With Mixed Inocula

Infection is defined by a positive urine or urethral swab culture. The proportion of infected participants by Day 6 with N. gonorrhoeae was assessed in each trial among participants with infections initiated with mixed inocula. Participants could become infected and received treatment any day before or on day 6. (NCT03840811)
Timeframe: day of infection, any day between Day 2 and Day 6

Interventionproportion of participants (Number)
Mixed FA1090/FA75371.00

[back to top]

Proportion of Participants With Occurrence of Bacteriuria in Non-competitive Infections, by Strain

Bacteriuria is defined as Log10 cfu N. gonorrhoeae/mL urine sediment. (NCT03840811)
Timeframe: Day of occurrence, any day between Day 2 and Day 6

Interventionproportion of participants (Number)
Mutant FA75370.86
Wild-type FA10901.00

[back to top]

Proportion of Participants With Occurrence of Signs and Symptoms of Urethritis Attributable to Gonococcal Infection in Non-competitive Infections, by Strain

Participants with any subjective symptoms or objective signs (observed urethral discharge) during period 01 (post-inoculation and before treatment which can occur on or before day 6) from the Solicited Events Form were captured. (NCT03840811)
Timeframe: Day of occurrence, any day between Day 2 and Day 6

Interventionproportion of participants (Number)
Mutant FA75371.00
Wild-type FA10901.00

[back to top]

Proportion of Participants With Occurrence of Urethritis in Non-competitive Infections

Urethritis is defined as >= 5.8 Log10 WBC/mL urine sediment. (NCT03840811)
Timeframe: Day of occurrence, any day between Day 2 and Day 6

Interventionproportion of participants (Number)
Mutant FA75371.00
Wild-type FA10901.00

[back to top]

The Competitive Index of the Mutant Compared to Wild Type Proportion of Organisms With the Predicted Competitive Advantage Recovered From Urine and/or Urethral Swab Specimens From Infected Participants

"The competitive index (CI) is defined by the ratio of colony forming units (cfu) of the two strains recovered from urine cultures on the day of treatment (output) compared to the ratio of strains in the inoculum (input):~CI = mutant cfu(output)/wild-type cfu(output) ÷ mutant cfu(input)/wild-type cfu(input).~The CI is used to assess whether the fitness of a given mutant is different than that of wild-type, and CI as a ratio is compared to 1. If it's not significantly different than 1, then no significant difference in the fitness was observed. Mutant or wild-type cfu values of 0 were replaced by 1 in the calculation of competitive index.~The assessment was performed in the MtrD trial mixed group." (NCT03840811)
Timeframe: Baseline and the day of treatment, any day between Day 2 and Day 6

Interventionratio (Median)
Mixed FA1090/FA753715.11

[back to top]